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ABSTRACT 
The American University in Cairo 
Molecular Characterization of Extended-Spectrum-β-Lactamases (ESBL) Producing 
Klebsiella pneumoniae and Escherichia coli among Hospitalized Patients in Oman 
Lobna Mohamed Mourad 
Advisers: Dr. Guillermo Pimentel and Dr. Rania Siam 
Hospital-acquired infections due to ESBL-producing gram-negative rods are a 
worldwide healthcare problem causing substantial patient morbidity and mortality.  In the 
Middle East, a significant increase in incidence and prevalence has been reported recently 
due to the misuse of antibiotics and lack of coherent antimicrobial resistance (AR) 
surveillance programs. The aim of the study was to determine the level of genotypic 
diversity and mechanism of AR of E. coli and K. pneumoniae ESBL-producing isolates 
from nosocomial infections among patients in Oman. 35 E. coli and 14 K. pneumoniae 
isolates were used in the study. Antibiotic susceptibility testing (AST) and ESBL 
screening was conducted via disk diffusion and E-test following CLSI (Clinical and 
Laboratory Standards Institute) guidelines. ESBL producers were screened for blaCTX-M, 
blaSHV, blaOXA, and blaTEM resistance markers via PCR. All PCR amplicons were 
sequenced to determine their allelic variants. In order to demonstrate overall genotypic 
diversity, Pulsed-Field Gel Electrophoresis (PFGE) analyses were done separately for all 
E. coli and K. pneumoniae isolates. 40 (80%) isolates were determined to be ESBL 
producing bacteria (27 E. coli and 13 K. pneumoniae). The highest level of AR (>70%) 
was against tetracycline, ampicillin, nalidixic acid, cephalothin, and cefpodoxime. The 
lowest level of AR was against chloramphenicol, amikacin and ticarcillin-clavulanic acid. 
 
4 
Resistance against imipenem was not detected. Similarity of K. pneumoniae isolates 
ranged from 61% to 100%. Three K. pneumoniae clusters (n= 7; 58%) had ≥ 80% 
similarity suggesting high level of similarity. E. coli PFGE analyses showed an overall 
similarity of 64% with 4 clusters (n= 14; 54%) showing 80% similarity. No correlation 
was demonstrated between the AR pattern and genotypic similarity for either species. 
Percentages of isolates with genetic markers for blaCTX-M, blaSHV, blaTEM, and blaOXA 
were 73%, 24%, 68%, and 60% respectively. DNA sequencing analyses revealed that the 
most common AR mechanism in these ESBL isolates is due to blaCTX-M-15 marker. In 
addition, SHV-1, SHV-11, SHV-12, TEM-1, and OXA-1 contribute to the overall AR 
mechanisms in nosocomial ESBL isolates from Oman. This is the first study 
characterizing the AR mechanism of ESBL’s isolates from hospital-acquired infections in 
Oman. The results showed that hospital-acquired E. coli isolates from Oman are more 
diverse than K. pneumoniae. The blaCTX-M-15 is the most abundant mechanism conferring 
ESBL phenotype on E. coli and K. pneumoniae, while the ESBL-SHV-type was the least 
abundant.  
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I. LITERATURE REVIEW 
In the early 1980s, third-generation cephalosporins were an important therapeutic tool 
in treating severe bacterial infections due to β-lactamase-mediated resistance (Colodner, 
2005; Perez et al., 2007). However, after the emergence of cephalosporin-resistant 
(including ceftazidime) Escherichia coli and Klebsiella pneumoniae strains, the efficacy 
of these antibiotics in saving lives was significantly compromised. According to Knothe 
et al. (1983) there are three main characteristics that cause result in resistance to beta-
lactam antibiotics: (1) production of beta-lactamases from chromosomal or plasmid 
genes; (2) changes in the active site(s) resulting in the loss of the ability to bind with the 
antibiotics; and (3) “Trapping” of the non-hydrolyzed antibiotics by highly induced 
lactamases, which prevents drug transportation and uptake. The β-lactamase enzymes 
were discovered in the early 1980s. These new beta-lactamase enzymes, called extended-
spectrum-beta-lactamases (ESBLs), were found in common enteric bacilli and showed 
distinct hydrolytic properties. The first ESBL enzymes discovered were shown to be 
mainly derived from the original TEM and SHV β-lactamases as a result of point 
mutations in the original enzymes resulting in the enzymes’ “extended spectrum” of 
action (Falagas and Karageorgopoulos, 2009). For example, significant resistance was 
characterized by single amino acid changes such as: Gly238Ser; Glu240Lys; 
Arg164Ser; Arg164His; Asp179 Asn, and; Glu(Asp)104Lys (Perez et al., 
2007). Currently, the presence of these ESBLs is becoming a major health problem for 
hospitalized patients, tertiary hospitals, facilities that offer long-term care, and even in the 
community (Perez et al., 2007).    
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Beta-lactamases are known to be one of the most heterogeneous groups of resistance 
enzymes, with over 700 different beta-lactamases described. Although β-lactamases show 
a great deal of amino acid variability, they are known to share a common overall 
topology. The β-lactamases are globular proteins made up of alpha-helices and beta-
pleated sheets (Perez et al., 2007). ESBLs are known to have the capability of 
hydrolyzing several classes of antibiotics, such as penicillins, first-, second-, third-, and 
fourth-generation cephalosporins and the monobactam antibiotic aztreonam (Perez et al., 
2007). However, ESBL derivatives from the TEM and SHV families are inhibited by β-
lactamase inhibitors that are available commercially, such as clavulanic acid, sulbactam, 
or tazobactam. The inhibition of ESBLs by β-lactamase inhibitors is a crucial property 
that it is used in the laboratory in the form of a phenotypic test that identifies whether a 
certain bacterial isolate possesses an ESBL or not (Perez et al., 2007).  
1. TEM β-lactamases: 
The first TEM β-lactamase gene, designated ESBL gene as blaTEM-1, was discovered 
in E. coli and Salmonella enterica serovar Paratyphi soon after the introduction of 
ampicillin for clinical use in 1965 (Mroczkowska and Barlow, 2008). The TEM-1 
enzyme itself was first isolated from a Greek patient named Temoniera, from a blood 
culture of an E. coli isolate.  
Since that time, the TEM-1 β-lactamase has been shown to occur world-wide and is 
currently thought to be the most common resistance mechanism against β-lactam 
antibiotics in Gram-negative bacilli (Sturenburg and Mack, 2003). During the 1970s, 
blaTEM-1 became widespread among Enterobacteriaceae and by the early 1980s was 
known to be the most prevalent resistance gene among clinical microbial populations. 
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The TEM-1 β-lactamase is known to confer resistance primarily against penicillins, 
including ampicillin (Mroczkowska and Barlow, 2008): up to 50-60% of plasmid-
mediated ampicillin resistance in E. coli is due to TEM-1 β-lactamase. TEM-1 is known 
to be located on Tn3, a promiscuous transposon, in which it appears that several 
rearrangement and transposition events resulted in the migration of the TEM-1 gene to 
other bacterial strains, such as Haemophilus influenza and Neisseria gonorrhoeae 
(Sturenburg and Mack, 2003).  
TEM-1 as well as its biochemical twin, TEM-2, hydrolyze penicillins and first-
generation cephalosporins; however, they cannot hydrolyze the oxyimino cephalosporins 
(Sturenburg and Mack, 2003).  In 1987, TEM-3 was the first TEM variant reported to 
have an increased activity against the extended-spectrum cephalosporins. Since then the 
number and variety of extended-spectrum TEM variants has increased rapidly. TEM is 
one of the most commonly found ESBL enzyme types in E. coli and K. pneumoniae, in 
which over 160 different variants are found in this family (Colodner, 2005; Mroczkowska 
and Barlow, 2008).  
The point mutations that are clustered in particular areas of the enzyme are what 
determine the broader spectrum of resistance. As described by Joris et al. (1991) these 
point mutation sites are adjacent to four evolutionarily conserved structural regions that 
form the active site of the enzyme (Sturenburg and Mack, 2003). It has been shown that 
in the progenitor enzyme all these elements are very close to the active site, in which it is 
thought that the amino acid substitutions result in the enlargement of the active site 
resulting in novel enzyme-substrate interactions that take place between the large 
oxyimino substituents of the extended-spectrum cephalosporins (Sturenburg and Mack, 
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2003). In fact, the accelerated evolution of the blaTEM sequence and phenotypic diversity 
presents it as a good model for studying the principles of evolutionary biology with 
clinical applications (Mroczkowska and Barlow, 2008).   
Genetic recombination as well as protein engineering have demonstrated novel β-
lactamases phenotypes. For example, ceftazidime resistant mutants can be generated 
using a wide variety of techniques such as insertional mutagenesis, site-directed and site-
saturation mutagenesis, random replacement mutagenesis, DNA shuffling, and random 
insertional deletional strand exchange mutagenesis (Babic et al., 2006). These 
experiments are mainly used in order to show how many substitutions can be generated to 
alter the TEM-1 phenotype. In some cases these experiments predicted the emergence of 
novel phenotypes before they appeared clinically (Babic et al., 2006).  
The fact that some blaTEM alleles confer resistance against cephalosporins and 
penicillins might indicate the possible increased prevalence of these alleles due to their 
advantageous phenotypes. Therefore, it is predicted that ESBL blaTEM alleles would 
either co-exist with blaTEM-1 or replace it as it is the most frequently found allele in 
clinical settings where cephalosporins are mainly used (Babic et al., 2006). However, 
neither of these predictions has yet proven to be true among clinical bacterial isolates, 
and blaTEM-1 is still the most common allele conferring resistance to first-line 
cephalosporins (Mroczkowska and Barlow, 2008).     
2. SHV β-lactamases: 
 
The SHV-type ESBL is known to be one of the most common ESBL types in clinical 
isolates compared to other ESBL types. The designation SHV refers to the sulfhydryl 
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variable, inhibition of the SHV activity by p-chloromercuribenzoate is substrate-related; 
and varies depending on the substrate used for the assay; however, studies never 
confirmed the validity of this hypothesis (Paterson and Bonomo, 2005).  
The SHV β-lactamase family originally was found in Klebsiella spp.. The progenitor 
of the SHV family, SHV-1, is universally present in K. pneumoniae. It has been shown 
that in most K. pneumoniae strains, the SHV-1 gene can be found on the bacterial 
chromosome, which may suggest that this gene may have evolved in Klebsiella and was 
subsequently incorporated into a plasmid that resulted in its spread to other 
enterobacterial species (Sturenburg and Mack, 2003). SHV-1 confers resistance to 
ampicillin, piperacillin, and ticarcillin, which are broad-spectrum penicillins; however, 
they do not confer resistance to the oxyimino substituted cephalosporins.  
In 1983, three K. pneumoniae and one Serratia marcescens strains from patients in 
West Germany showed transferable resistance to cefotaxime and other new 
cephalosporins. Later it was shown that mutations in SHV-1 resulted in the emergence of 
the new plasmid-encoded β-lactamase, SHV-2, in which the amino acid at position 238 
was changed from glycine to serine resulting in enhancement of the affinity of the SHV-1 
β-lactamase to the oxyimino cephalosporins. In addition, this mutation led to a noticeable 
rise in the MIC to cefotaxime as well as slight rise in the MIC to ceftazidime (Sturenburg 
and Mack, 2003). Since that time, additional SHV ESBL variants have been reported 
containing various amino acid alterations, such as those in positions 179, 205, and 240, 
that contribute to an increased ESBL phenotype. Currently, there are over 40-SHV ESBL 
enzymes where changes in amino acid sequences have conferred the ability to hydrolyze 
the new cephalosporins (Sturenburg and Mack, 2003).  
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SHV ESBL-producing bacteria have been detected in various members of the 
Enterobacteriaceae. In addition, Pseudomonas aeruginosa and Acinetobacter spp. isolates 
have caused significant nosocomial outbreaks due to the production of ESBL by SHV 
enzymes (Paterson and Bonomo, 2005). Unlike TEM, only SHV-10 was reported as an 
SHV variant with an inhibitor resistant phenotype, where in position 130 the amino acid 
serine is replaced by glycine (Sturenburg and Mack, 2003). It was shown that SHV-2 and 
SHV-5 have the ability to hydrolyze cefepime where patients engaged in a retrospective 
study and infected with ESBL-producing bacteria with susceptibility to cefepime 
(Sturenburg and Mack, 2003).  
3. CTX-M β-lactamases: 
 
The CTX-M-type ESBLs now exceed over 40 different types, in which they are 
divided into five different clusters based on amino acid identities: group CTX-M-1 
includes CTX-M-1, -3, -10, -12, -15, -28, -30 and FEC-1; group CTX-M-2 includes 
CTX-M-2, -4, -5, -6, -7, -20, and Toho-1; group CTX-M-8 includes only CTX-M-8; 
group CTX-M-9 includes CTX-M-9, -13, -14, -16, -17, -19, -21, -24, -27, and Toho-2, 
and finally; group CTX-M-25 includes CTX-M-25 and CTX-M-26 (Pitout et al., 2005). 
CTX-M (cefotaxime) β-lactamases possess strong hydrolytic activity against cefotaxime. 
Bacterial isolates that possess CTX-M enzymes usually show MIC (minimum inhibitory 
concentration) levels against cefotaxime in the resistant range (>64 µg/ml), but MIC 
levels against ceftazidime in the susceptible range (2 to 8 µg/ml). However, it has been 
reported that some CTX-M positive isolates have the ability to hydrolyze ceftazidime, 
conferring resistance against this particular cephalosporin (Paterson and Bonomo, 2005). 
It has also been shown that cefepime is efficiently hydrolyzed by the CTX-M enzymes, 
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for which MIC levels against cefepime are higher than for other ESBL-producing 
bacteria.  
Unlike clavulanic acid, tazobactam shows a 10-fold inhibitory effect against CTX-M 
β-lactamases. It has been observed in several species that they harbor either both CTX-M 
and SHV ESBLs or CTX-M and AmpC β-lactamases. Toho-1 and Toho-2 β-lactamases 
are structurally related to the CTX-M β-lactamases. Similar to CTX-M β-lactamases, 
Toho-1 and Toho-2 hydrolytic activity is stronger against cefotaxime than ceftazidime 
(Paterson and Bonomo, 2005).  
There has been a rapid spread of the CTX-M β-lactamases, and they have now been 
detected on every continent. Previously, CTX-M β-lactamases were mainly found in 
three different geographical regions: South America, Eastern Europe, and, the Far East 
(Paterson and Bonomo, 2005). Although it was observed in the past that CTX-M β-
lactamases were infrequently detected in Western Europe and North America, the 
presence of CTX-M has been reported in recent years in these regions. Subsequently, the 
CTX-M β-lactamases have become widespread in India and China, and it is speculated by 
some that the CTX-M type of β-lactamases is the most frequent ESBL type. Several 
studies have shown the presence of identical CTX-M β-lactamases in different 
geographic areas, such as CTX-M-3 that was discovered in Poland and Taiwan (Paterson 
and Bonomo, 2005).  
4. OXA β-lactamases: 
 
OXA β-lactamases are named after their ability to hydrolyze oxacillin. They are 
predominantly found in P. aeruginosa but have been reported in several Gram-negative 
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species (Paterson and Bonomo, 2005). The hydrolysis rate of OXA β-lactamases for 
cloxacillin and oxacillin is known to be more than 50% compared to that of 
benzylpenicillin.  
The OXA ESBLs were discovered originally in P. aeruginosa samples from a 
hospital in Ankara, Turkey (Paterson and Bonomo, 2005). Novel derivatives of OXA-10, 
OXA013 and OXA-18 were discovered in France in P. aeruginosa isolates from hospital-
acquired infections. It has been shown that the ESBL OXA-type β-lactamases evolution 
from the parent enzymes with narrower spectra resembles the evolution of the TEM- and 
SHV-type ESBLs (Paterson and Bonomo, 2005). 
OXA-1 is the most common OXA β-lactamase with a prevalence rate of 1 to 10% in 
isolates of E. coli that possess an OXA β-lactamase (Paterson and Bonomo, 2005). Most 
of the OXA β-lactamases do not significantly hydrolyze the extended-spectrum 
cephalosporins and hence they are not considered to be ESBLs. However, OXA-10 is 
known to weakly hydrolyze cefotaxime, aztreonam, and ceftriaxone, resulting in most 
organisms having a reduced susceptibility to these antibiotics. OXA-11, -14, -15, -16, -
17, -18, -19, -28, -31, -32, -35, and -45, are all OXA ESBLs that confer resistance to 
cefotaxime, and in some cases ceftazidime and aztreonam (Paterson and Bonomo, 2005).  
5. Overview of ESBL Producing Bacteria in the Middle East: 
Since the 1980s, ESBL-producing bacteria have rapidly spread across many different 
geographical regions. This spread may be a result of the transmission of plasmids among 
unrelated Enterobacteriaceae, a phenomenon observed in French hospitals (Moubareck et 
al., 2005), or by the clonal dissemination of the enzyme-producing microorganisms. In 
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several cases, transfer of ESBL-producing bacteria between hospitals followed by their 
clonal expansion and/or horizontal transfer of plasmids with ESBL genes may take place. 
Although ESBL-producing bacteria have been reported in many countries, few studies 
providing antibiotic resistance (AR) data in the Middle East have been published. The 
majority of the studies performed to date represent only hospitalized patients where the 
transfer rate of ESBL from patient fecal flora to community subjects is still unknown 
(Moubareck et al., 2005). For example, a 5-year study in Lebanon (1997 - 2001), at Saint 
George Hospital, showed that among 4,299 E. coli and 1,248 K. pneumoniae isolates, 2% 
and 20%, respectively, were ESBL positive (Moubareck et al., 2005). However, no 
epidemiological studies on ESBL–producing bacteria have been conducted recently in 
Lebanon. Another study done by Moubareck et al. (2005) revealed that out of 118 
isolates, 72 (61%) were shown to be ESBL positive with E. coli being the most abundant 
ESBL carrier. Molecular data showed that CTX-M-15 was the most prevalent ESBL 
produced, while SHV-5a was detected in the remaining isolates (Moubareck et al., 2005). 
In Egypt, recent studies on Enterobacteriaceae revealed 70% AR rates to third-
generation cephalosporins (Khalaf et al., 2009). A survey from 2001 to 2002 covering 
medical centers in Northern and Southern European countries, Saudi Arabia, Lebanon, 
Egypt, and South Africa showed that the highest incidence of ESBL-producing bacteria 
was in Egypt. Recently, CTX-M-type ESBLs have been reported in Egypt, with CTX-M-
15 being the most prevalent ESBL reported in the Middle East and North Africa (Khalaf 
et al., 2009). Also, CTX-M-14 has been detected in Egypt and Tunisia. A study by 
Khalaf et al. (2009) showed that all 5 clinical isolates tested were ESBL positive and 
resistant to cefotaxime (CTX). Molecular analyses identified blaCTX-M-14 in K. 
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pneumoniae and Enterobacter cloacae and blaCTX-M-15 in E. coli. This study is considered 
to be the first report of CTX-M-14 in Egypt, North Africa, or the Middle East for K. 
pneumoniae and E. coli (Khalaf et al., 2009). 
In Saudi Arabia, a study by Al-Agamy et al. (2009) revealed that out of a total of 400 
K. pneumoniae isolates collected from two hospitals in Riyadh, 55% were ESBL positive. 
PCR analyses showed that 97.3%, 84.1%, and 34.1% of ESBL isolates were positive for 
SHV, TEM, and CTX-M β-lactamase genes, respectively. Also CTX-M-1 and CTX-M-9 
were identified with a prevalence of 60% and 40%, respectively (Al-Agamy et al., 2009). 
In Kuwait, a study by Ensor et al. (2008) showed that CTX-M-15 is the predominant 
ESBL gene among K. pneumoniae and E. coli isolates from both hospital and community 
patients. Another study in Oman by Al-Lawati et al. (2000) showed that 2 out of 13 E. 
coli isolates and 3 out of 20 Klebsiella spp. isolates were ESBL positive, in which they 
were resistant to aztreonam and ceftazidime, but sensitive to ceftazclav.             
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II. PROJECT OBJECTIVES  
Very minimal ESBL surveillance and molecular characterization studies has been 
carried out in the Middle East, which is a serious threat to the public health because 
of the increasing incidence of ESBL infections in the region. This study from Oman 
can be the start of a more thorough surveillance system throughout the Middle East. 
Isolates for this study were extracted from hospitalized patients with nosocomial 
infections in 2006. The objectives of the study are the following:  
 To determine the percentage of E. coli and K. pneumoniae isolates that produce 
ESBL enzymes. 
 To determine the AR mechanism of ESBL isolates by sequencing four resistant 
markers (blaCTX-M, blaSHV, blaTEM, and blaOXA) responsible for this phenotype. 
 To compare DNA and amino acid sequence of ESBL producing isolates from 
hospital-acquired infections in Oman to isolates from other geographical regions.  
 To determine the amount of genetic variability present in E. coli and K. 
pneumoniae isolates by molecular fingerprinting using Pulsed Field Gel 
Electrophoresis (PFGE).  
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III. MATERIALS AND METHODS 
 
1. Specimen Collection, Identification and Archiving: 
 
Bacterial isolates were donated for this study by Dr. Suleiman Busaidy, Director 
of the Central Public Health Laboratory (CPHL) in Oman.  Isolates were taken from 
patient blood cultures at Public Health Hospitals as part of routine care for suspected 
nosocomial infections (sepsis). Highly-resistant Gram-negative rods identified by clinical 
laboratories were transferred to Dr. Busaidy’s lab for further confirmation. Isolates were 
shipped to NAMRU-3 in chocolate agar slants at room temperature for advanced 
molecular characterization. 
At NAMRU-3 samples were processed for ESBL identification and long-term 
archiving. All isolates were cultured on MacConkey agar (Becton Dickinson, USA) in a 
non-CO2 incubator at 37°C for 24 hours. Phenotypic identification was carried out using 
the 5-biochemical differential tubes test (Kligler's Iron Agar, Motility Indole Ornithine 
Medium, Lysine Iron Agar, Simmons Citrate Agar and Urea Broth) (Becton Dickinson, 
USA), as per NAMRU-3 standard operating procedures (Manual of Clinical 
Microbiology, ASM, 2009). Confirmation of K. pneumoniae identity was carried out 
using the Analytical Profile Index for Enterobacteriaceae (API-20E) (BioMerieux, 
France). Following confirmation, isolates were inoculated aseptically using sterile cotton 
swabs (Becton Dickinson, USA) into 1.8 mL tubes and preserved in BrainHeart Infusion 
broth with 15% glycerol and stored at -70°C.  
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2. Antibiotic Susceptibility Testing (AST): 
 
AST was conducted and interpreted following CLSI (Clinical and Laboratory 
Standards Institute) guidelines and/or manufacturer’s instructions (CLSI, Wayne, PA 
USA). Tables 1 and 2 show the antibiotics tested using Kirby-Bauer and/or E-test (AB 
Biodisk, Solna, Sweden) methods, respectively, to determine the AR profile of each 
isolate. 
Briefly, a bacterial suspension was prepared using 0.85% saline solution and 
turbidity adjusted to the equivalent of a 0.5 McFarland Standard. A sterile cotton swab 
was dipped into the bacterial suspension and used to inoculate Mueller-Hinton agar plates 
in three directions to ensure uniform growth of bacteria. Inoculated plates were left for 15 
minutes to dry, antibiotic discs or E-test strips were placed on the agar surface using an 
automatic dispenser, and the plate incubated in a non-CO2 incubator at 37°C for 18-20 
hours. ESBL production was detected using the double-disk approximation method 
described by Jarlier et al. (1988). Utilizing CAZ or CTX in combination with clavulanic 
acid, the zone of inhibition was measured. A zone of inhibition ≥ 5 mm, when compared 
to CAZ or CTX without clavulanic acid, indicates an ESBL positive isolate (CLSI, 
Wayne, PA USA).   
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3. Pulsed-Field Gel Electrophoresis (PFGE): 
 
Methods to prepare bacterial plugs and DNA restriction digestion for ESBL-
producing E. coli and K. pneumoniae isolates were similar. Colonies were scraped from a 
MacConkey agar plate using a sterile cotton applicator and diluted in a cell suspension 
buffer (CSB) (1 M Tris, pH8.0, 0.5 M EDTA, pH 8.0) until an optical density of 0.5-0.55 
was achieved using a turbidity meter (Dade Behring, CA, USA).  An aliquot of bacterial 
suspension was gently mixed with an equal volume of melted agarose (pulsed field 
grade), and dispensed into pre-formed plug molds. PFGE plugs were made by 
transferring 400 µl of bacterial suspension into 1.5 ml reaction tubes that were mixed 
with 20 µl of proteinase K and 400 µl of the melted 1% SeaKem Gold Agarose(SKG): 
1% sodium dodecyl sulfate (SDS) (47.5 ml of TE buffer, 2.5 ml 20% SDS and 0.5 g 
SKG). Immediately, the mixture was dispensed into the wells of the plug molds and left 
to solidify for 20 minutes. After the plugs solidified, they were transferred into 50 ml 
falcon tubes containing 5 ml cell lysis buffer (CLB) (1 M Tris, pH8.0, 0.5 M EDTA, pH 
8.0, 5 g Sarcosyl) and 25 µl proteinase K. The BD Falcon 50-ml conical tubes were 
incubated at 54°C in a shaker for 2 hours with vigorous shaking. After incubation, the 
lysis buffer was discarded and plugs were washed twice with 10-ml sterile water and four 
times with 10-ml TE buffer. Each wash was for 20 minutes and after the final wash the 
plugs were stored in TE buffer at 4°C until digestion.  
Bacterial DNA was digested using the XbaI enzyme (New England BioLabs, 
Ipswich, MA, USA). Salmonella enterica ser. Braenderup (Tenover et al., 1995) was 
used as control and ladder to determine DNA fragment sizes and genetic relationships 
among isolates based on PFGE patterns. Briefly, each plug was cut with a razor blade 
 
17 
into a 2-mm slice and placed into a 1.5-ml tube with 200 µl of incubation buffer (180 µl 
sterile water and 20 µl 10X NE buffer (New England BioLabs, Ipswich, MA, USA)). 
Tubes were incubated at 37°C in a water bath for 15 minutes. The restriction solution was 
prepared by mixing 1755 µl of distilled-sterile water, 200 µl 10X NE buffer (New 
England BioLabs, Ipswich, MA, USA), 20 µl 100X BSA (New England BioLabs, 
Ipswich, MA, USA), and 25 µl 20,000 U/ml XbaI (New England BioLabs, Ipswich, MA, 
USA). After incubation, the 200-μl incubation buffer was discarded and 200 µl of 
restriction solution was added to the plugs. Tubes were incubated in a water bath at 37°C 
for 4 hours. Later, the restriction solution was discarded and 200 µl of 0.5 X TBE were 
added to the tubes. After restriction, the plugs were loaded into a 1% SKG agarose gel 
(0.5 X TBE). Plugs were placed at the bottom of a 10-well comb with control plugs at 
both ends. The plugs were dried using tissue paper to ensure no excess buffer remained in 
the plugs. Agarose gel was poured into the casting gel tray, left to solidify for 30 minutes 
and loaded into the buffer chamber of a CHEF DRII or DRIII pulsed field apparatus 
(Bio-Rad, Hercules, CA, USA) containing 0.5X TBE at 14°C. PFGE running conditions 
were as following: 6.0 V/cm for 19 hours for K. pneumoniae and 20 hours for E. coli at 
switch times from 2.2-54.2 seconds. PFGE patterns were observed by staining the gel 
with ethidium bromide for 20 minutes and de-staining three times with distilled water for 
20 minutes each. Photos were taken with the Gel Doc XR System (Bio-Rad, Hercules, 
CA, USA). The banding pattern of the gels was then analyzed and dendograms were 
generated using the BioNumerics software. 
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4. Detection of Antimicrobial Resistance Alleles via PCR and Sequencing: 
 
DNA extraction was carried out using the SV Minipreps Promega DNA 
Purification System (Promega, Madison, WI, USA) according to the manufacturer’s 
instructions. Amplification of the blaTEM, blaSHV, blaCTX-M, and blaOXA genetic markers 
was carried out in a final volume of 25 µl using the following reaction: 10X buffer 
(Promega, Madison, WI, USA ), 10 µM  dNTP mix (Promega), 30µM PCR-specific 
forward primer, 30µM PCR-specific reverse primer, 5U/µl Taq polymerase (Promega, 
Madison, WI, USA), 25 µM MgCl2 (Promega, Madison, WI, USA), 2 μl DNA and 
Molecular Biology Grade water. The PCR reactions were conducted in a GeneAmp PCR 
System 9700 (Applied Biosystems, Carlsbad, CA, USA). The amplicon-specific primers 
are shown in Table 3 (Chen et al., 2004).  
PCR Cycling Conditions 
Genes Initial denaturation 
(1 cycle) 
Amplification cycles (30 times) Final extension 
(1 cycle) 
blaTEM 94°C 5 min 94°C 30 sec, 52°C 45 sec and 72°C 
45 sec 
72°C 7 min 
blaSHV 95°C 10 min 95°C 30 sec, 55°C 1 min and 72°C 1 
min 
72°C 7 min 
blaCTX-M 94°C 5 min 94°C 30 sec, 57°C 45 sec and 72°C 
45 sec 
72°C 7 min 
blaOXA 94°C 5 min 94°C 30 sec, 52°C 45 sec and 72°C 
45 sec 
72°C 7 min 
 
PCR amplicons were analyzed by gel electrophoresis on 1.5% agarose gel (Bio-
Rad, Hercules, CA, USA) using 1X TBE (Promega, Madison, WI, USA ) as running 
buffer. The gels were run at 100V for 40 minutes followed by staining for 20 minutes on 
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ethidium bromide and destaining for 30 minutes with distilled water. Gels were 
visualized and photographed under UV light.  
5. Sequencing Reactions: 
 
Only isolates that showed a single PCR amplicon were selected for sequencing 
analyses. Forward and reverse sequencing was carried out for all amplified targets. After 
amplification, the PCR amplicons were purified and sequenced. In the purification step, 
10 µl of the PCR product was added to 5 µl of ExoSAP-IT reagent (USB, Cleveland, 
Ohio) and the mixture was incubated in a thermocycler for 15 minutes at 37°C followed 
by 15 minutes at 80°C. The purified PCR product was then subjected to cycle sequencing 
using the Big Dye Fluorescent System (Applied Biosystems, Carlsbad, CA, USA). The 
reaction was carried out in a total volume of 20 μl with the following reagents: 2 µl of the 
purified PCR product, 5X sequencing buffer (Applied Biosystems, Carlsbad, CA, USA), 
Big Dye Terminator V3.15X (Applied Biosystems, Carlsbad, CA, USA), molecular 
biology grade water, and either 3 µM forward primer or 3µM reverse primer. The 
sequencing reaction was performed under the following conditions: initial denaturation at 
96°C for 10 sec, followed by 25 cycles of 96°C for 10 sec, 50°C for 5 sec and 60°C for 4 
min. Reactions were kept at 4°C or stored at -20°C until purification of the sequenced 
products using the Performa Gel Filtration Cartridge (Edge Biosystems, Gaithersburg, 
Maryland, USA) according to manufacturer’s instructions. 10 µl of sequenced products 
were loaded into the ABI 3100 (Applied Biosystems, Carlsbad, California, USA) 
automated sequencer plate. 
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6. Sequence Data Analyses: 
 
 The nucleotide sequences were compared using BLAST and analyzed using the 
BioEdit Clustal W program (Hall TA., 1999) as well as the BioNumerics software 
(Applied Maths, Inc. Austin, TX). Sequences were first assembled, aligned, and edited 
using the BioNumerics software. After that, sequences were imported to BioEdit where 
they were aligned with a known sequence and edited further. The nucleotide sequence 
was then converted to the amino acid sequence. The amino acid sequences were analyzed 
using the website http://www.lahey.org/studies/, which is maintained by the Lahey 
Clinic, in order to assign a specific TEM, SHV, CTX-M, or OXA allele to each isolate.   
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IV. RESULTS 
1. Antimicrobial Susceptibility and ESBL Screening 
 50 Gram negative isolates were collected in 2006 from blood cultures of patients 
with suspected nosocomial infections at Public Health Hospitals in Oman. Out of 50 
isolates (36 E. coli and 14 K. pneumoniae) tested, 40 (80%) were confirmed as ESBL-
producing. Out of the 40 isolates, 27 (75%) E. coli and 13 (92.8%) K. pneumoniae, are 
ESBL producing species, which was determined using the double-disk approximation 
method as described in the materials and methods section. Antibiotic susceptibility 
testing showed that the highest level of AR (>70%) was against five different antibiotics, 
AM, CF, CPD, NA, and TE (Figure 3), in which the results were interpreted according to 
the measurement of the zone of inhibition using the CLSI standard guidelines. 47 (94%) 
isolates showed resistance against ampicillin (AM), which implies that it should not be 
used in treating nosocomial infections caused by ESBL-producing bacteria. Also 46 
(92%) of the isolates were resistant to cephalothin (CF) also suggesting the poor 
antimicrobial activity of this particular agent against ESBL bacteria. Cefpodoxime 
(CPD), nalidixic acid (NA), and tetracycline (TE) all demonstrated high resistance 
ranging from 82% to 74%. On the other hand, the lowest level of AR (≤16%) was shown 
against chloramphenicol (C), amikacin (AN) and ticarcillin-clavulanic acid (TIM) where 
16% to 6% of the isolates were resistant to these three antimicrobial agents, suggesting 
the effectiveness of these antibiotics against ESBL-producing bacteria (Figure 3). The 
decreased percentage of resistance against ticarcillin-clavulanic acid (TIM) can highly be 
due to the fact that ticarcillin is combined with clavulanic acid, which is a β-lactamase 
inhibitor, and hence less number of bacteria species survived. This is also the case with 
ampicillin/sulbactam (SAM); however, the a higher percentage of resistance was 
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observed for this compound and this can be due to either the strength of ampicillin as an 
antimicrobial agent or decreased effectiveness of sulbactam as a β-lactamase inhibitor 
compared to that of clavulanic acid.  
No resistance was detected against imipenem (IPM), in which none of the isolates 
was resistant to IPM suggesting the effectiveness of this antimicrobial agent against 
ESBL bacteria (Figure 3). Therefore, in terms of susceptibility, 100% of all the isolates 
were susceptible to IPM (Figure 1). In terms of intermediate resistance, Ticarcillin-
clavulanic acid (TIM) was shown to have the highest number of intermediate isolates (n= 
22), which also suggests the poor antimicrobial activity of this agent against ESBL 
bacteria (Figure 2). Based on E-test, 76% of the isolates conferred resistance to 
ceftriaxone (TX), while 50% of the isolates were susceptible to cefepime (PM) (Table 4). 
The E-test results indicate that less resistance has been observed against fourth generation 
cephalosporins (PM) compared to the antimicrobial agent that belongs to the third 
generation cephalosporins (TX).   
2. Characterization of ESBL Genes 
The forty isolates that tested positive for ESBL production were then analyzed to 
identify the type of ESBL present. Plasmid DNA was extracted and PCR utilized for the 
four major type markers. The percentages of isolates carrying the plasmid-encoded 
genetic markers, blaCTX-M, blaSHV, blaTEM, and blaOXA were 73%, 24%, 68%, and 60% 
respectively. The band sizes for blaCTX-M, blaSHV, blaTEM, and blaOXA were 766 bp, 720 
bp, 650 bp, and 600 bp respectively (Figures 4, 5, 6, & 7).  
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Twenty-one E. coli and 8 K. pneumoniae isolates were positive for blaCTX-M 
(Figure 4). These CTX-M type ESBL genes were then sequenced using the Big Dye 
protocol to identify the subtypes present. DNA sequencing analyses using the BioEdit 
and BioNumerics software packages, revealed that all blaCTX-M positive isolates carried 
the CTX-M-15 allele (Figures 8 a & b). Isolate 06-012018 initially tested negative for 
any ESBL phenotype (i.e. no resistance to 3
rd
 or 4
th
-generation cephalosporins). 
However, PCR and sequencing analyses subsequently demonstrated that it was positive 
for only CTX-M-15, which implies that the isolate did not possess the ESBL phenotype 
due to the ESBL gene not being expressed (Table 5). 
Isolates of K. pneumoniae (n=10) were the only ones with blaSHV markers (i.e. no 
E. coli isolates possessed the SHV type of ESBL), which is usually the case presented by 
the Klebsiella spp. (Figure 5). Subsequent sequencing analyses using the Lahey Clinic 
webpage, amino acid sequences revealed that 4 isolates possessed the SHV-11 subtype, 4 
isolates the SHV-12 subtype, and the SHV-1 subtype was detected in 2 isolates (Figures 
11 a & b). This indicates that sequencing analyses showed that only 8 isolates possessed 
the ESBL SHV-type, since SHV-1 is not categorized as an ESBL.  
According to the PCR amplification, thirty-two isolates were positive for blaTEM 
allele (Figure 6). All of these isolates (16 E. coli and 6 K. pneumoniae) carried the 
blaTEM-1 subtype showing that no ESBL TEM-type isolates have identified, since the 
TEM-1 is the parent enzyme from which ESBL TEM-types later originated (Figures 9 a 
& b). In addition, sequencing analyses revealed that all OXA-positive isolates (18 E. coli 
and 4 K. pneumoniae) were shown to possess the most common OXA allele, OXA-1 
allele (Figure 7, 10 a & b).  
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3. Genotypic Analyses 
PFGE was carried out in order to establish the genotypic fingerprint of the E. coli 
and K. pneumoniae isolates separately. As shown in the materials and methods section, 
the protocol for preparing the PFGE gels for both species was the same; however, there 
were only slight differences in the running conditions of the E. coli and K. pneumoniae 
gels. The PFGE banding pattern for both species was analyzed using the BioNumerics 
software, in which the DNA fragment sizes and genetic relationships were determined 
using the Salmonella enterica ser. Braenderup as control and ladder to determine. 
According to the PFGE gel analysis, similarity between the K. pneumoniae isolates 
ranged from 61% to 100% (Figure 13). PFGE results for K. pneumoniae revealed that all 
isolates clustered in two main clusters and a single outlier. Only two K. pneumoniae 
isolates (06-012053 and 06-012055) were shown to be indistinguishable (i.e. 100% 
similarity). However, in order to claim that these two particular isolates are identical 
more thorough epidemiological work needs to be carried out. As for E. coli isolates, they 
clustered in 4 main groups revealing an overall similarity of 64% (Figure 12). Similar to 
K. pneumoniae, only 2 E. coli isolates (06-012012 and 06-012029), were shown to be 
indistinguishable. For both species, there was no significant correlation found between 
the AR patterns and genotypic (as judged by PFGE similarity). The lack of correlation is 
due to the fact that the PFGE investigated the genotypic properties of the isolates, while 
the AR patterns tested for the ESBL phenotype. 
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V. DISCUSSION 
Studies that characterize the AR mechanisms of ESBL-producing bacteria are 
essential to monitor the evolution and spread of ESBL genes and to establish a sound AR 
surveillance system that guides antibiotic prescription and use policies. ESBL-producing 
organisms represent a major threat to public health, but may be effectively controlled, 
partly by continuing epidemiological studies and solid pharmaceutical research aimed at 
enhancing the development of new β-lactam antibiotics effective against ESBL-
producing bacteria. The Middle East region currently lacks thorough epidemiological 
studies investigating ESBL prevalence as well as robust surveillance systems. Therefore, 
more ESBL characterization studies are needed in order to monitor the spread of ESBL 
genes in the region and control the spread of ESBL-producing bacteria throughout 
hospitals and in the community. 
This study was conducted as part of a larger study that investigated the increasing 
distribution of ESBL-producing bacteria among countries in the Persian Gulf and 
particularly  illustrated the increasing percentage of ESBL-producing bacteria in Oman. 
Oman is a Middle Eastern country with a total population of 2.577 million, out of which 
1.844 million are Omanis. Around 600,000 expatriates are known to live in Oman, most 
of whom are from Pakistan, Egypt, The Philippines, Bangladesh and India - all 
developing countries where the prevalence of ESBLs is known to be high (Encyclopedia 
of the Nations, 2010).  
In this study, 80% (40/50) of analyzed Gram-negative bacilli tested positive for 
the ESBL phenotype. Compared to other published regional studies this percentage is 
substantially high, suggesting the possible misuse of antibiotic therapy by the general 
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public. A study at the intensive care unit (ICU) at the Royal Hospital in Oman showed 
that every 100 patients treated in the ICU received an antibiotic treatment for 916 days 
average, which were mainly third-generation cephalosporins, ciprofloxacin, amikacin, 
and imipenem. According to this study the antibiotic consumption increased by 50% 
from 1996 to 2000. With this substantial antibiotic use, it is not surprising to observe the 
noticeable change in the microbial ecology in terms of high incidence of resistance 
among the bacteria (Al-Lawati et al., 2000). Also as noted by Al-Tawfiq et al. (2010) that 
a study from Oman reported that 31% of the urinary tract community E. coli were 
resistant to ciprofloxacin. According to Al-Tawfiq et al. (2010) the high incidence of 
antimicrobial resistance in the Middle East in general is due to number of reasons, such 
as the wide availability of over-the-counter antibiotics, patient-self medication, lack of 
public awareness in proper antibiotic use. Another explanation for the high percentage of 
ESBL bacteria could be due to the regular movement of immigrants from developing 
countries conducting manual labor in Oman.  
The isolates provided for this study were collected in 2006 from the blood of 
hospitalized patients suffering from nosocomial infections at public health hospitals in 
Oman. Both ampicillin (a penicillin) and cephalothin (a cephalosporin) showed the 
highest levels of resistance among the isolates, 94% and 92%, respectively. Both of these 
antibiotic groups contain the characteristic beta-lactam ring that is targeted by the 
different beta-lactamases produced by most Gram-negative and very few Gram-positive 
bacteria. Alternatively, 100% of the tested strains were shown to be susceptible to 
imipenem, which suggests the effectiveness of imipenem as a course of treatment for 
patients suffering from nosocomial infections with ESBL positive bacterial species. 
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Based on results from the E-test method, which allows the determination of the 
MIC for each antibiotic tested, cephalothin was shown to have the highest level of 
resistance (90% of strains); while, 50% of isolates were susceptible to cefepime. The 
majority of isolates susceptible to cefepime were E. coli, with only one K. pneumoniae 
isolate (06-012047) being susceptible. According to such findings it can be deduced that 
cefepime would be more effective than cephalothin in the course of treatment against β-
lactamase-producing E. coli. In other words, the highest resistance levels found were 
against a first-generation antibiotic, while the fourth-generation antibiotic was shown to 
be more effective against E. coli isolates. This type of surveillance can help guide treating 
physicians on which antibiotics are most appropriate and effective.    
The main goal of performing PFGE on the isolates was to establish a genotypic map 
and to determine whether or not PFGE genotype correlated with ESBL profile. The E. 
coli dendogram contained 26 isolates that ranged in similarity from 64% to 100%. The 26 
isolates clustered into 4 main clusters, out of which 14 isolates were shown to have 80% 
or more similarity, resulting in 54% of the total number of E. coli isolates being ≥80% 
similar. Isolates 06-012012 and 06-012029 were shown to be indistinguishable with 
100% similarity. As for K. pneumoniae, the similarity among the 12 isolates ranged from 
61% to 100 %, forming three main clusters. Among these three clusters, 7 isolates (58%) 
were shown to be ≥80% similar. Also, isolates 06-012053 and 06-012055 were shown to 
have 100% similarity making these two isolates indistinguishable, which according to 
Tenover et al., indicates that these two isolates represent the same strain and suggest as 
well that the isolates might have been part of an outbreak (Tenover et al., 1995). Since 
54% of the E. coli isolates and 58% of the K. pneumoniae isolates were shown to be 
 
28 
≥80% similar, the isolates for both bacterial species are considered to be closely related. 
According to Tenover et al. isolates are assigned to the closely related category when the 
PFGE pattern differs by 2 or 3 fragments from that of an outbreak. Such pattern changes 
can be due to a single genetic event, such as a deletion, an insertion, or a point mutation 
(Tenover et al., 1995).  In this study in was determined that  PFGE genotype (pattern) did 
not correlate with antibiotic resistance profile (including the E-test). In other words,  no 
correlation could be established between the PFGE genotype and the ESBL phenotype. 
This lack of correlation may be due to the fact that PFGE typing is based on differences 
detected in the complete genome, while the ESBL typing only targets the specific ESBL 
genetic markers.  
Studies conducted in other regions have shown significant genotypic diversity among 
isolates. According to Mendonca et al. (2009) a study in Portugal showed that 108 K. 
pneumoniae isolates identified 65 different PFGE profile types out of which only two 
turned out to have 100% similarity. In another study in Spain, Sorlozano et al. (2007) 
showed that a different PFGE pattern was obtained for each of the 8 clinical isolates 
studied. In Mexico, Mosqueda-Gomez et al. (2008) identified 54 different genotypes out 
of the 121 isolates typed, in which 21 isolates were shown to be unique while the other 
100 clustered in 33 different genotypes with each containing two to four isolates. Such 
data from other studies show that the isolates in this study reveal a close genetic 
relatedness as well as genotypic similarities unlike other regions. Similarly, the PFGE 
results of a study in neonatal intensive care unit of a Kuwaiti hospital by Dashti et al. 
(2010) showed that all isolates have an identical banding pattern, which indicates that the 
bloodstream infections have been caused by a single clone of ESBL producing K. 
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pneumoniae. PFGE is a very useful laboratory tool that helps identifying accurately an 
outbreak situation. Since outbreak isolates are of the same species and known to be both 
genetically and epidemiologically related, they generally share the same PFGE banding 
pattern in terms of number of bands and band size.                
Determining the AR mechanism of ESBL-producing strains is crucial because it helps 
monitor the spread and transmission of these ESBL-producing genes as well as 
maintaining a sound surveillance system that could provide guidance in appropriate 
courses of treatment to those suffering such bacterial infections. According to these 
analyses, all blaCTX-M positive isolates contained specifically the CTX-M-15 allelic 
variant. This allele has been shown to be the most common CTX-M type allele in several 
Middle Eastern countries, such as Kuwait, Lebanon, Egypt, and Saudi Arabia (Ensor et 
al,, 2009; Moubareck et al,, 2005; Al-Agamy et al,, 2006; Khalaf et al,, 2009; Al-Agamy 
et al,, 2009). Given the population mobility in and out of Oman from countries where 
CTX-M is known to be prevalent, our high positive percentage (73%) could be related to 
these regional movement events.  
It has been observed that there is a high prevalence of CTX-M groups in both hospital 
and community settings (Pitout et al., 2005), which obscures treatment for several 
diseases such as urinary tract infections (Ehlers et al., 2009). According to Ehlers et al. 
the occurrence of the CTX-M ESBLs affects public health by facilitating the spread of 
infection from the hospital to the community. Therefore, such ESBL-producing bacteria, 
especially the ones carrying CTX-M-type markers, require strict and efficient AR 
surveillance systems and careful treatment policy guidance in order to prevent increasing 
local AR rates (Ehlers et al., 2009).  
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Based on sequence analyses for blaSHV, SHV-11, SHV-12, and SHV-1 were the only 
allelic variants detected. Previous studies have shown that K. pneumoniae isolates are 
most likely to have SHV genes as the predominant AR mechanism (Sturenburg and 
Mack, 2003). A study in Iran by Shahcheraghi et al. (2007) demonstrated that SHV was 
the dominant ESBL enzyme in K. pneumoniae strains. Another study also in Iran by 
Feizabadi et al. (2010) revealed that the SHV types characterized were SHV-5, SHV-11, 
and SHV-12: all found in K. pneumoniae strains. According to Lee et al. (2006), K. 
pneumoniae produces class A chromosomal β-lactamases that are resistant to ampicillin, 
ticarcillin, amoxicillin, and carbenicillin (Lee et al., 2006). In clinical K. pneumoniae 
isolates, three families of chromosomal β-lactamases have been identified, SHV, LEN, 
and OKP. Plasmid-mediated SHV-type ESBLs are very common in K. pneumoniae 
isolates, in which SHV-12 is known to be common in south-east Asia (Lee et al., 2006). 
In the study by Lee et al. the ESBL incidence was more common in K. pneumoniae 
isolates containing the blaSHV-11 gene than it is in isolates containing the blaSHV-1 gene. 
Also it was demonstrated that a number of the K. pneumoniae isolates carrying the 
blaSHV-11 gene, also produced the ESBL SHV-12 subtype. However, the abundance of 
SHV-12 in chromosomal blaSHV-11 gene-containing strains remains unknown (Lee et al., 
2006). Also it is worth mentioning that SHV-1 is not considered an ESBL type since it is 
the parent enzyme from which precursors of ESBL SHV-type later evolved. According to 
Lee et al. it is possible to identify a chromosomal SHV as well as a plasmid SHV in the 
same isolate; therefore, the three SHV-types identified could have co-existed in a single 
isolate if chromosomal DNA was extracted as well. Since blaSHV is known to be more 
common in chromosomal DNA, this represents a limitation in the study because if 
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additional to plasmid DNA, chromosomal DNA was extracted, the percentage of SHV-
positive isolates might have been higher.  
Several studies have shown the abundance of SHV-1, -11, and -12 types in 
southwestern Asia and the Middle East. Bali et al. (2010) showed that SHV-12 in K. 
pneumoniae and E. coli, is one of the most common ESBLs reported in Turkey. On the 
other hand, in Palestine Hussein et al. (2009) demonstrated that among 60 Gram-negative 
bacterial isolates from Palestinian hospitals in 2006, both blaSHV-1 and blaSHV-12 were 
identified among ESBL types found.      As for blaTEM, analyses revealed that all isolates 
were the TEM-1 subtype, which is not considered to be an ESBL as the TEM-1 subtype 
is the parent enzyme from which more TEM precursors with ESBL phenotype later 
originated. However, it is important to mention that such a result could be due to the use 
of a particular set of primers that were unable to discriminate between the different TEM 
families. In other words, the upstream and downstream primers are used to discriminate 
between closely related TEM subtypes; however, in this case only the primer detecting 
the core region of the gene was used and hence all isolates were characterized as TEM-1. 
Our study suggest that TEM is not a significant factor conferring the ESBL phenotype on 
E. coli and K. pneumoniae isolates from hospital-acquired infections in Oman. Due to the 
fact that blaTEM-1 was shown to be the most common allele in this study, it can be 
hypothesized that the bacteria might have a selective advantage expressing blaTEM-1 more 
than other alleles in the blaTEM family. As was shown in studies in Turkey, Palestine, and 
Kuwait, only blaTEM-1 was identified from the TEM family (Hussein et al., 2009; Bali et 
al., 2010; Dashti et al., 2010). In Turkey 50% of the isolates were positive for TEM (Bali 
et al., 2010), while a study in Saudi Arabia revealed that 84.1% of the isolates were TEM 
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positive (Al-Agamy et al., 2009). The lack of ESBL TEM allele in several countries of 
the Middle East region suggest decline of the ESBL TEM incidence compared to the 
rapid increase of CTX-M prevalence. Regarding blaOXA, analysis showed that all the 
isolates were OXA-1 which is known to be the most common OXA β-lactamase 
especially in E. coli. Also OXA-1 is known to be the most common the Middle East 
region, such as in Palestine, OXA-1 was identified in hospital isolates (Hussein et al., 
2009).  
Since the AR mechanisms identified were all located in plasmids, this facilitates the 
transfer and spread of these AR mechanisms in a geographical location. However, more 
epidemiological and molecular characterization studies need to be carried out in order to 
address this concept as well as monitor the spread of ESBL bacterial isolates in the 
region.             
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VI. CONCLUSION 
Antibiotic resistance among Gram-negative bacteria represents a global challenge 
with the increased resistance to β-lactam antibiotics. According to Hanson (2010), there 
are two main strategies by which scientists can overcome the problem of resistance; the 
first is to develop new combinations of antibiotics faster than the development of 
resistance. The second strategy is to develop the technology that would enable scientists 
to carry out thorough and rapid surveillance of resistant bacteria both in community and 
hospital settings. The rapid detection and identification of resistance can lead to judicious 
antibiotic use, which will minimize the existence and development of more resistance.      
This study revealed that a high incidence of ESBL-producing E. coli and K. 
pneumoniae was present in hospital-acquired infections in Oman. Genotypic analysis 
showed that both the E. coli and K. pneumoniae isolates were highly diverse suggesting 
that it is more than a single strain circulating. DNA sequencing analysis revealed that 
blaCTX-M-15 is the most prevalent ESBL producing gene found in hospital-acquired E. coli 
and K. pneumoniae isolates in Oman. The other ESBL genes revealed by the analyses 
were blaTEM-1, blaSHV-1, blaSHV-11, blaSHV-12, and blaOXA-1. This study highlighted the 
importance of the need to improve the surveillance system of antibiotic resistance and 
resistance mechanisms in the Middle East. In addition, it is crucial to organize public 
awareness campaigns since they are necessary to encourage responsible antibiotic use.  
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VIII. TABLES AND FIGURES 
Antibiotics Tested via the Disk Diffusion Method 
Antibiotic 
Discs  
Antibiotic Name Antibiotic 
Concentration 
C Chloramphenicol 30 µg 
CRO Ceftriaxone 30 µg 
AN Amikacin 30 µg 
SXT Trimethoprim-sulfamethoxazole 1.25/23.75 µg 
TE Tetracycline 30 µg 
CIP Ciprofloxacin 5 µg 
GM Gentamicin 10 µg 
AM Ampicillin 10 µg 
NA Nalidixic Acid 30 µg 
IPM Imipenem 10 µg 
FEP Cefepime 30 µg 
ATM Aztreonam 30 µg 
SAM Ampicillin/Sulbactam 10/10 µg 
CF Cephalothin 30 µg 
TIM Ticarcillin-clavulanic acid 75/10 µg 
CPD Cefpodoxime 10 µg 
CAZ Ceftazidime 30 µg 
CTX Cefotaxime 30 µg 
 
Table 1: table showing the 18 different antibiotics (AB Biodisk, Solna, Sweden) tested 
via the disk diffusion method and the drug concentration for each particular antibiotic. 
The ATCC
®
 controls (E. coli 25922, S. aureus 25923, P. aeruginosa 27853) were used to 
test the efficiency of the antibiotic discs. 
  
Antibiotics Tested via E-test  
E-Test Strips E-Test Name 
TZ Ceftazidime 
PM Cefepime 
CE Cephalothin 
TX Ceftriaxone 
 
Table 2: table showing the antibiotics (AB Biodisk, Solna, Sweden) tested via E-test. The 
ATCC
®
 control (E. coli 25922) was used to test the efficiency of the antibiotic strips. 
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Forward and Reverse Primers Utilized for PCR of ESBL Genes  
ESBL 
Genes 
Forward (5’—3’) Reverse (5’ – 3’) Size (bp) 
blaTEM-1 CAG CGG TAA GAT CCT TGA GA ACT CCC CGT CGT GTA GAT AA 643 
blaSHV-1 GGC CGC GTA GGC ATG ATA GA CCC GGC GAT TTG CTG ATT TC 714 
blaCTX-M AAC CGT CAC GCT GTT GTT AG TTG AGG CTG GGT GAA GTA AG 766 
blaOXA-1 AAT GGC ACC AGA TTC AAC TT CTT GGC TTT TAT GCT TGA TG 595 
 
Table 3: this table shows the primers used to amplify the four specific gene markers. The 
TEM primer amplifies the blaTEM gene (858 bp), SHV primer amplifies the blaSHV gene 
(861 bp), CTX-M primer amplifies the blaCTX-M gene (876 bp), and OXA primer 
amplifies the blaOXA gene (869 bp) (Chen et al., 2004). 
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Figure 1: A bar graph showing the susceptibility of the 50 isolates against the 18 
different antibiotics tested, measured by the zone of inhibition using the CLSI standards. 
All isolates (100%) were susceptible to IPM. AN was the second antibiotic to which 88% 
of the isolates were susceptible. On the other hand, the majority of the isolates presented 
the least susceptibility against AM and CF.    
 
 
Figure 2: A bar graph showing the percentage of the isolates that are found in the 
intermediate region between the susceptibility and resistance, measured by the zone of 
inhibition using the CLSI standards. According to the data 44% of the isolates were 
resistant to TIM. 
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Figure 3: A bar graph showing the resistance of the 50 isolates against the 18 different 
antibiotics tested, measured by the zone of inhibition using the CLSI standards. 
According to the data, 94% of the isolates were resistant to AM, while 92% were resistant 
to CF making it the second in terms of resistance. On the other hand, all isolates (100%) 
showed no resistance to IPM. Also, only 6% of the isolates were resistant to AN making 
it the second antibiotic after IPM to have the highest efficacy. 
Antimicrobial Resistance Spectrum Tested via E-Test 
E-Test Name Resistance (%) Intermediacy 
(%) 
Susceptibility (%) 
TZ Ceftazidime 24% 40% 36% 
PM Cefepime 20% 30% 50% 
CE Cephalothin 90% 8% 2% 
TX Ceftriaxone 76% 4% 20% 
 
Table 4: The E-test data shows the four different antibiotics tested and the percentages of 
the isolates resistant, intermediate, and susceptible to each particular antibiotic, by 
determining the minimum inhibitory concentration using the CLSI standards. 76% of the 
isolates were resistant to TX, while 50% of the isolates were susceptible to PM.  
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Amplification of CTX-M: 
 
Figure 4: PCR gel showing the amplification of the blaCTX-M gene. Isolates were 
categorized to be positive for blaCTX-M if a single sharp band has been amplified. 73% of 
the 40 ESBL positive isolates possessed the blaCTX-M gene. A 100 bp DNA ladder was 
used as a molecular marker (M). 
 
Amplification of SHV: 
 
Figure 5: PCR gel showing the amplification of the blaSHV gene. Isolates were 
categorized to be positive for blaSHV if a single sharp band has been amplified. 24% of the 
40 ESBL positive isolates possessed the blaSHV gene. A 100 bp DNA ladder was used as a 
molecular marker (M).  
 
 
Band size 766 bp 
Band size 720 bp 
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Amplification of TEM: 
 
Figure 6: PCR gel showing the amplification of the blaTEM gene. Isolates were 
categorized to be positive for blaTEM if a single sharp band has been amplified. 68% of the 
40 ESBL positive isolates possessed the blaTEM gene. A 100 bp DNA ladder was used as 
a molecular marker (M).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Band size 650 bp 
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Amplification of OXA: 
 
Figure 7: PCR gel showing the amplification of the blaOXA gene. Isolates were 
categorized to be positive for blaOXA if a single sharp band has been amplified. 60% of 
the 40 ESBL positive isolates possessed the blaOXA gene. A 100 bp DNA ladder was used 
as a molecular marker (M). 
 
 
 
 
 
 
 
 
 
 
 
 
Band size 600 bp 
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CTX-M Nucleic Acid Sequence Alignment 
 
CTXMF1_Oman(06-012014)  -GCaACCGTCACGCTGTTGTTAGGAAGTGT GCCGCTGTAT GCGCAAACGG CGGACGTACA  
CTXMF1_Oman(06-012015)   GGCaACCGTC ACGCTGTTGT TAGGAAGTGT GCCGCTGTAT GCGCAAACGG 
CGGACGTACA  
CTXMF1_Oman(06-012016)   GGCaACCGTC ACGCTGTTGT TAGGAAGTGT GCCGCTGTAT GCGCAAACGG 
CGGACGTACA  
 
CTXMF1_Oman(06-012014)   GCAAAAACTT GCCGAATTAG AGCGGCAGTC GGGAGGCAGA CTGGGTGTGG 
CATTGATTAA  
CTXMF1_Oman(06-012015)   GCAAAAACTT GCCGAATTAG AGCGGCAGTC GGGAGGCAGA CTGGGTGTGG 
CATTGATTAA  
CTXMF1_Oman(06-012016)   GCAAAAACTT GCCGAATTAG AGCGGCAGTC GGGAGGCAGA CTGGGTGTGG 
CATTGATTAA  
 
CTXMF1_Oman(06-012014)   CACAGCAGAT AATTCGCAAA TACTTTATCG TGCTGATGAG CGCTTTGCGA 
TGTGCAGCAC  
CTXMF1_Oman(06-012015)   CACAGCAGAT AATTCGCAAA TACTTTATCG TGCTGATGAG CGCTTTGCGA 
TGTGCAGCAC  
CTXMF1_Oman(06-012016)   CACAGCAGAT AATTCGCAAA TACTTTATCG TGCTGATGAG CGCTTTGCGA 
TGTGCAGCAC  
 
CTXMF1_Oman(06-012014)   CAGTAAAGTG ATGGCCGCGG CCGCGGTGCT GAAGAAAAGT GAAAGCGAAC 
CGAATCTGTT  
CTXMF1_Oman(06-012015)   CAGTAAAGTG ATGGCCGCGG CCGCGGTGCT GAAGAAAAGT GAAAGCGAAC 
CGAATCTGTT  
CTXMF1_Oman(06-012016)   CAGTAAAGTG ATGGCCGCGG CCGCGGTGCT GAAGAAAAGT GAAAGCGAAC 
CGAATCTGTT  
 
CTXMF1_Oman(06-012014)   AAATCAGCGA GTTGAGATCA AAAAATCTGA CCTTGTTAAC TATAATCCGA 
TTGCGGAAAA  
CTXMF1_Oman(06-012015)   AAATCAGCGA GTTGAGATCA AAAAATCTGA CCTTGTTAAC TATAATCCGA 
TTGCGGAAAA  
CTXMF1_Oman(06-012016)   AAATCAGCGA GTTGAGATCA AAAAATCTGA CCTTGTTAAC TATAATCCGA 
TTGCGGAAAA  
 
CTXMF1_Oman(06-012014)   GCACGTCAAT GGGACGATGT CACTGGCTGA GCTTAGCGCG GCCGCGCTAC 
AGTACAGCGA  
CTXMF1_Oman(06-012015)   GCACGTCAAT GGGACGATGT CACTGGCTGA GCTTAGCGCG GCCGCGCTAC 
AGTACAGCGA  
CTXMF1_Oman(06-012016)   GCACGTCAAT GGGACGATGT CACTGGCTGA GCTTAGCGCG GCCGCGCTAC 
AGTACAGCGA  
 
CTXMF1_Oman(06-012014)   TAACGTGGCG ATGAATAAGC TGATTGCTCA CGTTGGCGGC CCGGCTAGCG 
TCACCGCGTT  
CTXMF1_Oman(06-012015)   TAACGTGGCG ATGAATAAGC TGATTGCTCA CGTTGGCGGC CCGGCTAGCG 
TCACCGCGTT  
CTXMF1_Oman(06-012016)   TAACGTGGCG ATGAATAAGC TGATTGCTCA CGTTGGCGGC CCGGCTAGCG 
TCACCGCGTT  
 
CTXMF1_Oman(06-012014)   CGCCCGACAG CTGGGAGACG AAACGTTCCG TCTCGACCGT ACCGAGCCGA 
CGTTAAACAC  
CTXMF1_Oman(06-012015)   CGCCCGACAG CTGGGAGACG AAACGTTCCG TCTCGACCGT ACCGAGCCGA 
CGTTAAACAC  
CTXMF1_Oman(06-012016)   CGCCCGACAG CTGGGAGACG AAACGTTCCG TCTCGACCGT ACCGAGCCGA 
CGTTAAACAC  
 
CTXMF1_Oman(06-012014)   CGCCATTCCG GGCGATCCGC GTGATACCAC TTCACCTCGG GCAATGGCGC 
AAACTCTGCG  
CTXMF1_Oman(06-012015)   CGCCATTCCG GGCGATCCGC GTGATACCAC TTCACCTCGG GCAATGGCGC 
AAACTCTGCG  
CTXMF1_Oman(06-012016)   CGCCATTCCG GGCGATCCGC GTGATACCAC TTCACCTCGG GCAATGGCGC 
AAACTCTGCG  
 
CTXMF1_Oman(06-012014)   GAATCTGACG CTGGGTAAAG CATTGGGCGA CAGCCAACGG GCGCAGCTGG 
TGACATGGAT  
CTXMF1_Oman(06-012015)   GAATCTGACG CTGGGTAAAG CATTGGGCGA CAGCCAACGG GCGCAGCTGG 
TGACATGGAT  
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CTXMF1_Oman(06-012016)   GAATCTGACG CTGGGTAAAG CATTGGGCGA CAGCCAACGG GCGCAGCTGG 
TGACATGGAT  
 
CTXMF1_Oman(06-012014)   GAAAGGCAAT ACCACCGGTG CAGCGAGCAT TCAGGCTGGA CTGCCTGCTT 
CCTGGGTTGT  
CTXMF1_Oman(06-012015)   GAAAGGCAAT ACCACCGGTG CAGCGAGCAT TCAGGCTGGA CTGCCTGCTT 
CCTGGGTTGT  
CTXMF1_Oman(06-012016)   GAAAGGCAAT ACCACCGGTG CAGCGAGCAT TCAGGCTGGA CTGCCTGCTT 
CCTGGGTTGT  
 
CTXMF1_Oman(06-012014)   GGGGGATAAA ACCGGCAGCG GTGGCTATGG CACCACCAAC GATATCGCGG 
TGATCTGGCC  
CTXMF1_Oman(06-012015)   GGGGGATAAA ACCGGCAGCG GTGGCTATGG CACCACCAAC GATATCGCGG 
TGATCTGGCc  
CTXMF1_Oman(06-012016)   GGGGGATAAA ACCGGCAGCG GTGGCTATGG CACCACCAAC GATATCGCGG 
TGATCTGGCC  
 
CTXMF1_Oman(06-012014)   AAAAGATCGT GCGCCGCTGA TTCTGGTCAC TTACTTCACC CAGCCTCAAC 
CTAAGGCAGA  
CTXMF1_Oman(06-012015)   AAAAGATCGT GCGCCGCTGA TTCTGGTCAC TTACTTCACC CAGCCTCAAC 
CTAAGGCAGA  
CTXMF1_Oman(06-012016)   AAAAGATCGT GCGCCGCTGA TTCTGGTCAC TTACTTCACC CAGCCTCAAC 
CTAAGGCAGA  
 
CTXMF1_Oman(06-012014)   AAGCCGTCGC GATGTATtAG CGTC 
CTXMF1_Oman(06-012015)   AAGCCGTCGC GATGTATtAG CGTC 
CTXMF1_Oman(06-012016)   AAGCCGTCGC GATGTATtAG CgTC 
 
Figure 8a: the DNA sequence alignment of 3 E. coli isolates for the CTX-M gene. This 
alignment after the sequences have been imported from BioNumerics to BioEdit for DNA 
and amino acid sequence alignment.    
 
CTX-M Amino Acid Sequence Alignment 
CTXMF1_Oman(06-012014)   ATVTLLLGSV PLYAQTADVQ QKLAELERQS GGRLGVALIN TADNSQILYR ADERFAMCST  
CTXMF1_Oman(06-012015)   ATVTLLLGSV PLYAQTADVQ QKLAELERQS GGRLGVALIN TADNSQILYR ADERFAMCST  
CTXMF1_Oman(06-012016)   ATVTLLLGSV PLYAQTADVQ QKLAELERQS GGRLGVALIN TADNSQILYR ADERFAMCST  
 
CTXMF1_Oman(06-012014)   SKVMAAAAVL KKSESEPNLL NQRVEIKKSD LVNYNPIAEK HVNGTMSLAE 
LSAAALQYSD  
CTXMF1_Oman(06-012015)   SKVMAAAAVL KKSESEPNLL NQRVEIKKSD LVNYNPIAEK HVNGTMSLAE 
LSAAALQYSD  
CTXMF1_Oman(06-012016)   SKVMAAAAVL KKSESEPNLL NQRVEIKKSD LVNYNPIAEK HVNGTMSLAE 
LSAAALQYSD  
 
CTXMF1_Oman(06-012014)   NVAMNKLIAH VGGPASVTAF ARQLGDETFR LDRTEPTLNT AIPGDPRDTT SPRAMAQTLR  
CTXMF1_Oman(06-012015)   NVAMNKLIAH VGGPASVTAF ARQLGDETFR LDRTEPTLNT AIPGDPRDTT SPRAMAQTLR  
CTXMF1_Oman(06-012016)   NVAMNKLIAH VGGPASVTAF ARQLGDETFR LDRTEPTLNT AIPGDPRDTT SPRAMAQTLR  
 
CTXMF1_Oman(06-012014)   NLTLGKALGD SQRAQLVTWM KGNTTGAASI QAGLPASWVV GDKTGSGGYG 
TTNDIAVIWP  
CTXMF1_Oman(06-012015)   NLTLGKALGD SQRAQLVTWM KGNTTGAASI QAGLPASWVV GDKTGSGGYG 
TTNDIAVIWP  
CTXMF1_Oman(06-012016)   NLTLGKALGD SQRAQLVTWM KGNTTGAASI QAGLPASWVV GDKTGSGGYG 
TTNDIAVIWP  
 
CTXMF1_Oman(06-012014)   KDRAPLILVT YFTQPQPKAE SRRDVLA 
CTXMF1_Oman(06-012015)   KDRAPLILVT YFTQPQPKAE SRRDVLA 
CTXMF1_Oman(06-012016)   KDRAPLILVT YFTQPQPKAE SRRDVLA 
 
Figure 8b: the amino sequence alignment of 3 E. coli isolates for the CTX-M gene. This 
alignment after the DNA sequences have been translated to the amino acid sequences on 
the BioEdit for further analysis using the Lahey Clinic webpage.   
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TEM Nucleic Acid Sequence Alignment 
06-012015   TATGTAATGA TAATAATGGT TTCTTAGACG TCAGGTGGCA CTTTTCGGGG AAATGTGCGC  
06-012023   TGATGTCTGA TAATAATGGT TTCTTAGACG TCAGGTGGCA CTTTTCGGGG AAATGTGCGC  
06-012024   TGATGTCTGA TAATAATGGT TTCTTAGACG TCAGGTGGCA CTTTTCGGGG AAATGTGCGC  
 
06-012015   GGAACCCCTA TTTGTTTATT TTTCTAAATA CATTCAAATA TGTATCCGCT CATGAGACAA  
06-012023   GGAACCCCTA TTTGTTTATT TTTCTAAATA CATTCAAATA TGTATCCGCT CATGAGACAA  
06-012024   GGAACCCCTA TTTGTTTATT TTTCTAAATA CATTCAAATA TGTATCCGCT CATGAGACAA  
 
06-012015   TAACCCTGGT AAATGCTTCA ATAATATTGA AAAAGGAAGA GTATGAGTAT TCAACATTTT  
06-012023   TAACCCTGGT AAATGCTTCA ATAATATTGA AAAAGGAAGA GTATGAGTAT TCAACATTTT  
06-012024   TAACCCTGGT AAATGCTTCA ATAATATTGA AAAAGGAAGA GTATGAGTAT TCAACATTTT  
 
06-012015   CGTGTCGCCC TTATTCCCTT TTTTGCGGCA TTTTGCCTTC CTGTTTTTGC TCACCCAGAA  
06-012023   CGTGTCGCCC TTATTCCCTT TTTTGCGGCA TTTTGCCTTC CTGTTTTTGC TCACCCAGAA  
06-012024   CGTGTCGCCC TTATTCCCTT TTTTGCGGCA TTTTGCCTTC CTGTTTTTGC TCACCCAGAA  
 
06-012015   ACGCTGGTGA AAGTAAAAGA TGCTGAAGAT CAGTTGGGTG CACGAGTGGG TTACATCGAA  
06-012023   ACGCTGGTGA AAGTAAAAGA TGCTGAAGAT CAGTTGGGTG CACGAGTGGG TTACATCGAA  
06-012024   ACGCTGGTGA AAGTAAAAGA TGCTGAAGAT CAGTTGGGTG CACGAGTGGG TTACATCGAA  
 
06-012015   CTGGATCTCA ACAGCGGTAA GATCCTTGAG AGTTTTCGCC CCGAAGAACG TTTTCCAATG  
06-012023   CTGGATCTCA ACAGCGGTAA GATCCTTGAG AGTTTTCGCC CCGAAGAACG TTTTCCAATG  
06-012024   CTGGATCTCA ACAGCGGTAA GATCCTTGAG AGTTTTCGCC CCGAAGAACG TTTTCCAATG  
 
06-012015   ATGAGCACTT TTAAAGTTCT GCTATGTGGT GCGGTATTAT CCCGTGTTGA CGCCGGGCAA  
06-012023   ATGAGCACTT TTAAAGTTCT GCTATGTGGT GCGGTATTAT CCCGTGTTGA CGCCGGGCAA  
06-012024   ATGAGCACTT TTAAAGTTCT GCTATGTGGT GCGGTATTAT CCCGTGTTGA CGCCGGGCAA  
 
06-012015   GAGCAACTCG GTCGCCGCAT ACACTATTCT CAGAATGACT TGGTTGAGTA CTCACCAGTC  
06-012023   GAGCAACTCG GTCGCCGCAT ACACTATTCT CAGAATGACT TGGTTGAGTA CTCACCAGTC  
06-012024   GAGCAACTCG GTCGCCGCAT ACACTATTCT CAGAATGACT TGGTTGAGTA CTCACCAGTC  
 
06-012015   ACAGAAAAGC ATCTTACGGA TGGCATGACA GTAAGAGAAT TATGCAGTGC TGCCATAACC  
06-012023   ACAGAAAAGC ATCTTACGGA TGGCATGACA GTAAGAGAAT TATGCAGTGC TGCCATAACC  
06-012024   ACAGAAAAGC ATCTTACGGA TGGCATGACA GTAAGAGAAT TATGCAGTGC TGCCATAACC  
 
06-012015   ATGAGTGATA ACACTGCTGC CAACTTACTT CTGACAACGA TCGGAGGACC GAAGGAGCTA  
06-012023   ATGAGTGATA ACACTGCTGC CAACTTACTT CTGACAACGA TCGGAGGACC GAAGGAGCTA  
06-012024   ATGAGTGATA ACACTGCTGC CAACTTACTT CTGACAACGA TCGGAGGACC GAAGGAGCTA  
 
06-012015   ACCGCTTTTT TGCACAACAT GGGGGATCAT GTAACTCGCC TTGATCGTTG GGAACCGGAG  
06-012023   ACCGCTTTTT TGCACAACAT GGGGGATCAT GTAACTCGCC TTGATCGTTG GGAACCGGAG  
06-012024   ACCGCTTTTT TGCACAACAT GGGGGATCAT GTAACTCGCC TTGATCGTTG GGAACCGGAG  
 
06-012015   CTGAATGAAG CCATACCAAA CGACGAGCGT GACACCACGA TGCCTGCAGC AATGGCAACA  
06-012023   CTGAATGAAG CCATACCAAA CGACGAGCGT GACACCACGA TGCCTGCAGC AATGGCAACA  
06-012024   CTGAATGAAG CCATACCAAA CGACGAGCGT GACACCACGA TGCCTGCAGC AATGGCAACA  
 
06-012015   ACGTTGCGCA AACTATTAAC TGGCGAACTA CTTACTCTAG CTTCCCGGCA ACAATTAATA  
06-012023   ACGTTGCGCA AACTATTAAC TGGCGAACTA CTTACTCTAG CTTCCCGGCA ACAATTAATA  
06-012024   ACGTTGCGCA AACTATTAAC TGGCGAACTA CTTACTCTAG CTTCCCGGCA ACAATTAATA  
 
06-012015   GACTGGATGG AGGCGGATAA AGTTGCAGGA CCACTTCTGC GCTCGGCCCT TCCGGCTGGC  
06-012023   GACTGGATGG AGGCGGATAA AGTTGCAGGA CCACTTCTGC GCTCGGCCCT TCCGGCTGGC  
06-012024   GACTGGATGG AGGCGGATAA AGTTGCAGGA CCACTTCTGC GCTCGGCCCT TCCGGCTGGC  
 
06-012015   TGGTTTATTG CTGATAAATC TGGAGCCGGT GAGCGTGGGT CTCGCGGTAT CATTGCAGCA  
06-012023   TGGTTTATTG CTGATAAATC TGGAGCCGGT GAGCGTGGGT CTCGCGGTAT CATTGCAGCA  
06-012024   TGGTTTATTG CTGATAAATC TGGAGCCGGT GAGCGTGGGT CTCGCGGTAT CATTGCAGCA  
 
06-012015   CTGGGGCCAG ATGGTAAGCC CTCCCGTATC GCAGTTATCT ACACGACGGG GAGTCAGGCA  
06-012023   CTGGGGCCAG ATGGTAAGCC CTCCCGTATC GTAGTTATCT ACACGACGGG GAGTCAGGCA  
06-012024   CTGGGGCCAG ATGGTAAGCC CTCCCGTATC GCAGTTATCT ACACGACGGG GAGTCAGGCA  
 
06-012015   ACTATG 
06-012023   ACTATG 
06-012024   ACTATG 
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Figure 9a: the DNA sequence alignment of 3 E. coli isolates for the TEM gene. This 
alignment after the sequences have been imported from BioNumerics to BioEdit for DNA 
and amino acid sequence alignment.    
 
TEM Amino Acid Sequence Alignment 
06-012015   IIMVS*TSGG TFRGNVRGTP ICLFF*IHSN MYPLMRQ*PW *MLQ*Y*KRK SMSIQHFRVA  
06-012023   IIMVS*TSGG TFRGNVRGTP ICLFF*IHSN MYPLMRQ*PW *MLQ*Y*KRK SMSIQHFRVA  
06-012024   IIMVS*TSGG TFRGNVRGTP ICLFF*IHSN MYPLMRQ*PW *MLQ*Y*KRK SMSIQHFRVA  
 
06-012015   LIPFFAAFCL PVFAHPETLV KVKDAEDQLG ARVGYIELDL NSGKILESFR PEERFPMMST  
06-012023   LIPFFAAFCL PVFAHPETLV KVKDAEDQLG ARVGYIELDL NSGKILESFR PEERFPMMST  
06-012024   LIPFFAAFCL PVFAHPETLV KVKDAEDQLG ARVGYIELDL NSGKILESFR PEERFPMMST  
 
06-012015   FKVLLCGAVL SRVDAGQEQL GRRIHYSQND LVEYSPVTEK HLTDGMTVRE LCSAAITMSD  
06-012023   FKVLLCGAVL SRVDAGQEQL GRRIHYSQND LVEYSPVTEK HLTDGMTVRE LCSAAITMSD  
06-012024   FKVLLCGAVL SRVDAGQEQL GRRIHYSQND LVEYSPVTEK HLTDGMTVRE LCSAAITMSD  
 
06-012015   NTAANLLLTT IGGPKELTAF LHNMGDHVTR LDRWEPELNE AIPNDERDTT MPAAMATTLR  
06-012023   NTAANLLLTT IGGPKELTAF LHNMGDHVTR LDRWEPELNE AIPNDERDTT MPAAMATTLR  
06-012024   NTAANLLLTT IGGPKELTAF LHNMGDHVTR LDRWEPELNE AIPNDERDTT MPAAMATTLR  
 
06-012015   KLLTGELLTL ASRQQLIDWM EADKVAGPLL RSALPAGWFI ADKSGAGERG SRGIIAALGP  
06-012023   KLLTGELLTL ASRQQLIDWM EADKVAGPLL RSALPAGWFI ADKSGAGERG SRGIIAALGP  
06-012024   KLLTGELLTL ASRQQLIDWM EADKVAGPLL RSALPAGWFI ADKSGAGERG SRGIIAALGP  
 
06-012015   DGKPSRIAVI YTTGSQATM 
06-012023   DGKPSRIAVI YTTGSQATM 
06-012024   DGKPSRIAVI YTTGSQATM 
 
Figure 9b: the amino sequence alignment of 3 E. coli isolates for the TEM gene. This 
alignment after the DNA sequences have been translated to the amino acid sequences on 
the BioEdit for further analysis using the Lahey Clinic webpage.   
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OXA Nucleic Acid Sequence Alignment 
06-012014   TTATGGCATT TGATGCGGAA TAATAGATCA GAAAACCATA TTCAAATGGG ATAAAACCCC 
CAAAGGAATG  
06-012015   TTATGGCATT TGATGCGGAA TAATAGATCA GAAAACCATA TTCAAATGGG ATAAAACCCC 
CAAAGGAATG  
06-012019   TTATGGCATT TGATGCGGAA TAATAGATCA GAAAACCATA TTCAAATGGG ATAAAACCCC 
CAAAGGAATG  
 
06-012014   GAGATCTGGA ACAGCAATCA TACACCAAAG ACGTGGATGC AATTTTCTGT TGTTTGGGTT 
TCGCAAGAAA  
06-012015   GAGATCTGGA ACAGCAATCA TACACCAAAG ACGTGGATGC AATTTTCTGT TGTTTGGGTT 
TCGCAAGAAA  
06-012019   GAGATCTGGA ACAGCAATCA TACACCAAAG ACGTGGATGC AATTTTCTGT TGTTTGGGTT 
TCGCAAGAAA  
 
06-012014   TAACCCAAAA AATTGGATTA AATAAAATCA AGAATTATCT CAAAGATTTT GATTATGGAA 
ATCAAGACTT  
06-012015   TAACCCAAAA AATTGGATTA AATAAAATCA AGAATTATCT CAAAGATTTT GATTATGGAA 
ATCAAGACTT  
06-012019   TAACCCAAAA AATTGGATTA AATAAAATCA AGAATTATCT CAAAGATTTT GATTATGGAA 
ATCAAGACTT  
 
06-012014   CTCTGGAGAT AAAGAAAGAA ACAACGGATT AACAGAAGCA TGGCTCGAAA GTAGCTTAAA 
AATTTCACCA  
06-012015   CTCTGGAGAT AAAGAAAGAA ACAACGGATT AACAGAAGCA TGGCTCGAAA GTAGCTTAAA 
AATTTCACCA  
06-012019   CTCTGGAGAT AAAGAAAGAA ACAACGGATT AACAGAAGCA TGGCTCGAAA GTAGCTTAAA 
AATTTCACCA  
 
06-012014   GAAGAACAAA TTCAATTCCT GCGTAAAATT ATTAATCACA ATCTCCCAGT TAAAAACTCA 
GCCATAGAAA  
06-012015   GAAGAACAAA TTCAATTCCT GCGTAAAATT ATTAATCACA ATCTCCCAGT TAAAAACTCA 
GCCATAGAAA  
06-012019   GAAGAACAAA TTCAATTCCT GCGTAAAATT ATTAATCACA ATCTCCCAGT TAAAAACTCA 
GCCATAGAAA  
 
06-012014   ACACCATAGA GAACATGTAT CTACAAGATC TGGATAATAG TACAAAACTG TATGGGAAAA 
CTGGTGCAGG  
06-012015   ACACCATAGA GAACATGTAT CTACAAGATC TGGATAATAG TACAAAACTG TATGGGAAAA 
CTGGTGCAGG  
06-012019   ACACCATAGA GAACATGTAT CTACAAGATC TGGATAATAG TACAAAACTG TATGGGAAAA 
CTGGTGCAGG  
 
06-012014   ATTCACAGCA AATAGAACCT TACAAAACGG ATGGTTTGAA GGGTTTATTA TAAGCAAATC 
AGGACATAAA  
06-012015   ATTCACAGCA AATAGAACCT TACAAAACGG ATGGTTTGAA GGGTTTATTA TAAGCAAATC 
AGGACATAAA  
06-012019   ATTCACAGCA AATAGAACCT TACAAAACGG ATGGTTTGAA GGGTTTATTA TAAGCAAATC 
AGGACATAAA  
 
06-012014   TATGTTTTTG TGTCCGCACT TACAGGAA 
06-012015   TATGTTTTTG TGTCCGCACT tACAGGAA 
06-012019   TATGTTTTTG TGTCCGCACT TACAGGAA 
 
Figure 10a: the DNA sequence alignment of 3 E. coli isolates for the OXA gene. This 
alignment after the sequences have been imported from BioNumerics to BioEdit for DNA 
and amino acid sequence alignment.    
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OXA Amino Acid Sequence Alignment 
06-012014   YGI*CGIIDQ KTIFKWDKTP KGMEIWNSNH TPKTWMQFSV VWVSQEITQK IGLNKIKNYL KDFDYGNQDF  
06-012015   YGI*CGIIDQ KTIFKWDKTP KGMEIWNSNH TPKTWMQFSV VWVSQEITQK IGLNKIKNYL KDFDYGNQDF  
06-012019   YGI*CGIIDQ KTIFKWDKTP KGMEIWNSNH TPKTWMQFSV VWVSQEITQK IGLNKIKNYL KDFDYGNQDF  
 
06-012014   SGDKERNNGL TEAWLESSLK ISPEEQIQFL RKIINHNLPV KNSAIENTIE NMYLQDLDNS TKLYGKTGAG  
06-012015   SGDKERNNGL TEAWLESSLK ISPEEQIQFL RKIINHNLPV KNSAIENTIE NMYLQDLDNS TKLYGKTGAG  
06-012019   SGDKERNNGL TEAWLESSLK ISPEEQIQFL RKIINHNLPV KNSAIENTIE NMYLQDLDNS TKLYGKTGAG  
 
06-012014   FTANRTLQNG WFEGFIISKS GHKYVFVSAL TG 
06-012015   FTANRTLQNG WFEGFIISKS GHKYVFVSAL TG 
06-012019   FTANRTLQNG WFEGFIISKS GHKYVFVSAL TG 
 
Figure 10b: the amino sequence alignment of 3 E. coli isolates for the OXA gene. This 
alignment after the DNA sequences have been translated to the amino acid sequences on 
the BioEdit for further analysis using the Lahey Clinic webpage.   
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SHV Nucleic Acid Sequence Alignment 
06-012056   CGCTTTCCCA TGATGAGCAC CTTTAAAGTA GTGCTCTGCG GCGCAGTGCT GGCGCGGGTG 
GATGCCGGTG  
06-012055   CGCTTTCCCA TGATGAGCAC CTTTAAAGTA GTGCTCTGCG GCGCAGTGCT GGCGCGGGTG 
GATGCCGGTG  
06-012057   CGCTTTCCCA TGATGAGCAC CTTTAAAGTA GTGCTCTGCG GCGCAGTGCT GGCGCGGGTG 
GATGCCGGTG  
 
06-012056   ACGAACAGCT GGAGCGAAAG ATCCACTATC GCCAGCAGGA TCTGGTGGAC TACTCGCCGG 
TCAGCGAAAA  
06-012055   ACGAACAGCT GGAGCGAAAG ATCCACTATC GCCAGCAGGA TCTGGTGGAC TACTCGCCGG 
TCAGCGAAAA  
06-012057   ACGAACAGCT GGAGCGAAAG ATCCACTATC GCCAGCAGGA TCTGGTGGAC TACTCGCCGG 
TCAGCGAAAA  
 
06-012056   ACATCTTGCC GACGGCATGA CGGTCGGCGA ACTCTGCGCC GCCGCCATTA CCATGAGCGA 
TAACAGCGCC  
06-012055   ACACCTTGCC GACGGCATGA CGGTCGGCGA ACTCTGTGCC GCCGCCATTA CCATGAGCGA 
TAACAGCGCC  
06-012057   ACACCTTGCC GACGGCATGA CGGTCGGCGA ACTCTGCGCC GCCGCCATTA CCATGAGCGA 
TAACAGCGCC  
 
06-012056   GCCAATCTGC TGCTGGCCAC CGTCGGCGGC CCCGCAGGAT TGACTGCCTT TTTGCGCCAG 
ATCGGCGACA  
06-012055   GCCAATCTGC TGCTGGCCAC CGTCGGCGGC CCCGCAGGAT TGACTGCCTT TTTGCGCCAG 
ATCGGCGACA  
06-012057   GCCAATCTGC TGCTGGCCAC CGTCGGCGGC CCCGCAGGAT TGACTGCCTT TTTGCGCCAG 
ATCGGCGACA  
 
06-012056   ACGTCACCCG CCTTGACCGC TGGGAAACGG AACTGAATGA GGCGCTTCCC GGCGACGCCC 
GCGACACCAC  
06-012055   ACGTCACCCG CCTTGACCGC TGGGAAACGG AACTGAATGA GGCGCTTCCC GGCGACGCCC 
GCGACACCAC  
06-012057   ACGTCACCCG CCTTGACCGC TGGGAAACGG AACTGAATGA GGCGCTTCCC GGCGACGCCC 
GCGACACCAC  
 
06-012056   TACCCCGGCC AGCATGGCCG CGACCCTGCG CAAGCTGCTG ACCAGCCAGC GTCTGAGCGC 
CCGTTCGCAA  
06-012055   TACCCCGGCC AGCATGGCCG CGACCCTGCG CAAGCTGCTG ACCAGCCAGC GTCTGAGCGC 
CCGTTCGCAA  
06-012057   TACCCCGGCC AGCATGGCCG CGACCCTGCG CAAGCTGCTG ACCAGCCAGC GTCTGAGCGC 
CCGTTCGCAA  
 
06-012056   CGGCAGCTGC TGCAGTGGAT GGTGGACGAT CGGGTCGCCG GACCGTTGAT CCGCTCCGTG 
CTGCCGGCGG  
06-012055   CGGCAGCTGC TGCAGTGGAT GGTGGACGAT CGGGTCGCCG GACCGTTGAT CCGCTCCGTG 
CTGTCGGCGG  
06-012057   CGGCAGCTGC TGCAGTGGAT GGTGGACGAT CGGGTCGCCG GACCGTTGAT CCGCTCCGTG 
CTGCCGGCGG  
 
06-012056   GCTGGTTTAT CGCCGATAAG ACCGGAGCTG GCGAACGGGG TGCGCGCGGG ATTGTCGCCC 
TGCTTGGCCC  
06-012055   GCTGGTTTAT CGCCGATAAG ACCGGAGCTG GAAAGCCAGC TGTgCGcGGC CGCGTAGGCC 
TGATAGAAAT  
06-012057   GCTGGTTTAT CGCCGATAAG ACCGGAGCTA GCAAGCGGGG TGCGCGCGGG ATTGTCGCCC 
TGCTTGGCCC  
 
06-012056   GAATAACAAA GCAGAGCGC 
06-012055   GGATaaCTGG CCAGCGGCC 
06-012057   GAATAACAAA GCAGAGCGC 
 
Figure 11a: the DNA sequence alignment of 3 K. pneumoniae isolates for the SHV gene. 
This alignment after the sequences have been imported from BioNumerics to BioEdit for 
DNA and amino acid sequence alignment.    
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SHV Amino Acid Sequence Alignment 
06-012056   RFPMMSTFKV VLCGAVLARV DAGDEQLERK IHYRQQDLVD YSPVSEKHLA DGMTVGELCA AAITMSDNSA  
06-012055   RFPMMSTFKV VLCGAVLARV DAGDEQLERK IHYRQQDLVD YSPVSEKHLA DGMTVGELCA AAITMSDNSA  
06-012057   RFPMMSTFKV VLCGAVLARV DAGDEQLERK IHYRQQDLVD YSPVSEKHLA DGMTVGELCA AAITMSDNSA  
 
06-012056   ANLLLATVGG PAGLTAFLRQ IGDNVTRLDR WETELNEALP GDARDTTTPA SMAATLRKLL TSQRLSARSQ  
06-012055   ANLLLATVGG PAGLTAFLRQ IGDNVTRLDR WETELNEALP GDARDTTTPA SMAATLRKLL TSQRLSARSQ  
06-012057   ANLLLATVGG PAGLTAFLRQ IGDNVTRLDR WETELNEALP GDARDTTTPA SMAATLRKLL TSQRLSARSQ  
 
06-012056   RQLLQWMVDD RVAGPLIRSV LPAGWFIADK TGAGERGARG IVALLGPNNK AER 
06-012055   RQLLQWMVDD RVAGPLIRSV LSAGWFIADK TGAGKPAVRG RVGLIEMDNW PAA 
06-012057   RQLLQWMVDD RVAGPLIRSV LPAGWFIADK TGASKRGARG IVALLGPNNK AER 
 
Figure 11b: the amino sequence alignment of 3 K. pneumoniae isolates for the OXA 
gene. This alignment after the DNA sequences have been translated to the amino acid 
sequences on the BioEdit for further analysis using the Lahey Clinic webpage. 
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Isolate # 
PCR Gel 
Working 
# 
Antibiotic 
Resistance 
E-Test 
Resistance 
Pattern 
ESBL BlaCTX-M BlaTEM BlaOXA BlaSHV 
E. coli Isolates 
06-012011 -1 SXT, TE, CIP, GM, 
AM, NA, CF 
CE negative X X X X 
06-012012 1 CRO, TE, CIP, AM, 
NA, CF, CPD, CTX 
CE and TX positive X X OXA-1 X 
06-012013 2 CRO, SXT, TE, 
CIP, GM, AM, NA, 
FEP, ATM, SAM, 
CF, CPD, CAZ, 
CTX 
CE and TX positive  X X OXA-1 X 
06-012014 3 CRO, AN, SXT, TE, 
CIP, GM, AM, NA, 
FEP, ATM, SAM, 
CF, CPD, CAZ, 
CTX 
CE, TX, 
TZ, PM 
positive  CTX-M-15 X OXA-1 X 
06-012015 4 CRO, SXT, TE, 
CIP, GM, AM, NA, 
FEP, ATM, SAM 
CF, CPD, CAZ, 
CTX 
CE, TX, 
TZ, PM 
positive  CTX-M-15 
 
TEM-1 OXA-1 X 
06-012016 5 CRO, TE, CIP, AM, 
NA, ATM, CF, 
CPD, CAZ 
CE, TX, TZ positive  CTX-M-15 X X X 
06-012017 6 C, SXT, TE, CIP, 
GM, AM, NA, FEP, 
ATM, CF, CPD, 
CAZ, CTX 
CE, TX, 
TZ, PM 
positive  CTX-M-15 X X X 
06-012018 7 SXT, TE, CIP, NA None Negative CTX-M-15 X X X 
AR Profile and DNA Sequencing Analysis 
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06-012019 8 CRO, SXT, TE, 
CIP, GM, AM, NA, 
ATM, SAM, CF, 
CPD, CTX 
CE, TX, 
PM 
positive  CTX-M-15 X OXA-1 X 
06-012020 -2 SXT, TE, CIP, AM, 
NA, SAM, CF 
TX Negative X X X X 
06-012021 -3 SXT, TE, CIP, AM, 
NA, SAM, CF 
CE Negative X X X X 
06-012022 9 CRO, SXT, TE, 
CIP, GM, AM, NA, 
ATM, SAM, CF, 
TIM, CPD, CTX 
CE and TX positive  CTX-M-15 X OXA-1 X 
06-012023 10 CRO, SXT, TE, 
CIP, GM, AM, NA, 
ATM, SAM, CF, 
CPD, CTX 
CE, TX, 
PM 
positive  CTX-M-15 TEM-1 OXA-1 X 
06-012024 11 CRO, SXT, AM, 
NA, ATM, CF, 
CPD, CTX 
CE and TX positive  CTX-M-15 TEM-1 OXA-1 X 
06-012025 12 CRO, SXT, TE, 
CIP, GM, AM, NA, 
FEP, ATM, SAM, 
CF, CPD, CTX 
CE and TX positive  CTX-M-15 X OXA-1 X 
06-012026 13 CRO, TE, GM, AM, 
NA, ATM, CF,TIM, 
CPD, CTX 
CE and TX positive  CTX-M-15 TEM-1 OXA-1 X 
06-012027 14 CRO, TE, GM, AM, 
NA, ATM, SAM, 
CF, TIM, CPD, 
CTX 
CE and TX positive  CTX-M-15 TEM-1 OXA-1 X 
06-012028 15 CRO, SXT, TE, CE, TX, positive  CTX-M-15 X OXA-1 X 
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CIP, AM, NA, FEP, 
ATM, SAM, CF, 
CPD, CTX 
PM 
06-012029 16 CRO, TE, CIP, AM, 
NA, CF, TIM, CPD, 
CTX 
CE and TX positive  X X X X 
06-012030 17 CRO, SXT, TE, 
CIP, GM, AM, NA, 
CF, CPD, CAZ, 
CTX 
CE and TX positive  X TEM-1 OXA-1 X 
06-012031 18 CRO, TE, CIP, AM, 
NA, ATM, CF, TIM 
CE and TX positive  CTX-M-15 X OXA-1 X 
06-012032 19 TE, CIP, GM, AM, 
NA, ATM, CF, CPD 
CE positive  X X X X 
06-012033 -4 NA & CF None Negative X X X X 
06-012034 20 C, CRO, SXT, TE, 
CIP, GM, AM, NA, 
FEP, ATM, SAM, 
CF, CPD, CAZ, 
CTX 
CE, TX, 
TZ, PM 
positive  CTX-M-15 TEM-1 OXA-1 X 
06-012035 21 C, CRO, SXT, CIP, 
GM, AM, NA, 
ATM, CF, TIM, 
CPD, CTX 
CE and TX positive  CTX-M-15 TEM-1 OXA-1 X 
06-012036 -5 SXT, TE, CIP, AM, 
NA 
None Negative X X X X 
06-012037 22 CRO, SXT, TE, 
GM, AM, FEP, 
ATM, SAM, CF, 
CPD, CAZ, CTX 
CE and TX positive  CTX-M-15 TEM-1 OXA-1 X 
06-012038 -6 CIP None Negative X X X X 
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06-012039 23 CRO, TE, GM, AM, 
FEP, ATM, CF, 
CPD, CAZ, CTX 
CE, TX, 
TZ, PM 
positive  X TEM-1 X X 
06-012040 24 CRO, CIP, AM, 
NA, FEP, SAM, CF, 
CPD, CAZ, CTX 
CE and TX positive  X TEM-1 X X 
06-012041 25 C, CRO, SXT, TE, 
AM, FEP, ATM, 
SAM, CF, CPD, 
CTX 
CE and TX positive  CTX-M-15 TEM-1 X X 
06-012042 26 CRO, AN, SXT, TE, 
CIP, GM, AM, NA, 
FEP, ATM, SAM, 
CF, TIM, CPD, 
CAZ, CTX 
CE, TX, 
TZ, PM 
positive  CTX-M-15 TEM-1 OXA-1 X 
06-012043 -7 CIP & CF CE Negative X X X X 
06-012044 27 CRO, SXT, TE, 
CIP, AM, NA, CF, 
CPD 
CE and TX Positive X TEM-1 X X 
06-012045 28 C, CRO, SXT, TE, 
AM, NA, ATM, CF, 
CPD, CTX 
CE and TX Positive CTX-M-15 TEM-1 X X 
06-012046 29 CRO, SXT, TE, 
AM, CF, TIM, CPD, 
CTX 
CE and TX Positive CTX-M-15 TEM-1 X X 
 Klebsiella Isolates 
06-012047 
K. oxytoca 
30 CRO, AM, NA, 
ATM, CF, CPD 
CE, TX, 
PM 
positive  CTX-M-15 X X X 
06-012048 -8 AM, NA, ATM, CF, 
CPD 
CE Negative X X X X 
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06-012049 -9 AM & CF CE and TX Negative X X X X 
06-012050 31 C, CRO, SXT, TE, 
CIP, GM, AM, NA, 
ATM, SAM, CF 
CPD, CTX 
CE and TX positive  CTX-M-15 TEM-1 OXA-1 SHV-1 
06-012051 32 CRO, TE, CIP, AM, 
NA, FEP, CF, CPD, 
CAZ 
CE, TX, TZ positive  CTX-M-15 TEM-1 OXA-1 SHV-11 
06-012052 33 SXT, TE, CIP, AM, 
SAM, CF, CPD, 
CTX 
CE and TX positive  CTX-M-15 TEM-1 OXA-1 SHV-11 
06-012053 34 CRO, GM, AM, 
FEP, ATM, SAM, 
CF, CPD, CAZ, 
CTX 
CE and TX positive   X TEM-1 OXA-1 SHV-1 
06-012054 35 AN, TE, CIP, GM, 
AM, NA, ATM, 
CPD, CAZ 
CE and TZ positive  X TEM-1 X X 
06-012055 36 CRO, GM, AM, 
FEP, ATM, SAM, 
CF, CPD, CAZ, 
CTX 
CE and TX positive  CTX-M-15 TEM-1 X SHV-12 
06-012056 37 CRO, SXT, CIP, 
AM, NA, FEP, 
ATM, CF, CPD, 
CAZ, CTX 
CE, TX, TZ positive  CTX-M-15 X X SHV-11 
06-012057 38 C, CRO, SXT, TE, 
GM, AM, FEP, 
ATM, SAM, CF, 
CPD, CTX 
CE, TX, TZ positive  CTX-M-15 X X SHV-12 
06-012058 39 CRO, AM, NA, CE and TZ positive  X X X SHV-12 
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Table 5: table showing all the AR and sequencing data compiled. The gray shaded rows are the ESBL positive isolates, while the non-
shaded rows represent the ESBL negative isolates. The second column from the left refers to the working number by which the 
isolates are labeled in the previous PCR gels. The yellow highlighted row refers to isolate 06-012018 that is ESBL negative but was 
positive for CTX-M-15.   
ATM, CF, CPD, 
CAZ, CTX 
06-012059 40 C, CRO, TE, CIP, 
AM, NA, FEP, 
ATM, CF, CPD, 
CAZ, CTX 
CE and TX positive  CTX-M-15 X X SHV-11 
06-012060 41 TE, CIP, AM, ATM, 
CF, CPD, CAZ 
CE positive  X X X SHV-12 
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E. coli PFGE Dendogram 
 
Figure 12: the E. coli PFGE dendogram representing the genotypic relationship 
among 26 E. coli isolates. The isolates clustered into four main clusters according to 
their genotypic similarities. An overall similarity of 64% among the 4 clusters has 
been established. Isolates 06-012012 and 06-012029 were shown to be 
indistinguishable (100% similarity).   
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K. pneumoniae PFGE Dendogram 
 
 
Figure 13: the K. pneumoniae PFGE dendogram representing the genotypic 
relationship among 12 K. pneumoniae isolates. The isolates clustered into two main 
clusters according to their genotypic similarities and a single outlier. An overall 
similarity between the isolates ranged from 61% to 100% has been established. 
Isolates 06-012053 and 06-012055 were shown to be indistinguishable (100% 
similarity).   
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